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1 
1 SUMMARY 
 Alzheimer’s disease (AD) is a neurodegenerative pathology that affects an increasing number 
of elderly people. It is characterized by progressive impairment in cognition and memory and it 
is the most frequent cause of dementia, being responsible for 60 to 70 % of the cases over 65 
years (World Health Organization, 2015). 
The major neuropathological hallmarks of the disease are the deposition of neurofibrillary 
tangles and senile plaques, primarily in hippocampus, entorhinal cortex and neocortex, and a 
widespread neuronal loss (Hardy and Selkoe 2002). 
AD is divided in sporadic and familial (FAD) forms. FAD is caused by highly penetrating 
mutations in three genes involved in amyloid-β (Aβ) metabolism: the Aβ precursor protein (APP), 
the presenilin1 (PSEN1) and the presenilin2 (PSEN2) (Bertram and Tanzi 2011). 
The earliest pathological changes are believed to take place in the hippocampal formation and 
entorhinal cortex (Squire, Stark, Clark 2004). These regions are part of the medial temporal lobe 
and are fundamental for the encoding of new memories as well as for the fixation of recent ones. 
Moreover, they are among the first targets of the pathology in terms of tissue abnormalities and 
neuro-physiological alterations; these latter well correlate with memory deficits, being early 
symptoms of the disease (Sperling, Mormino, Johnson 2014; Squire, Stark, Clark 2004). 
The most prominent network activity patterns in the hippocampus are field potential 
oscillations in the theta (4 – 12 Hz) and gamma (30 – 100 Hz) frequency bands. Theta and gamma 
oscillations are considered to play a pivotal role in memory as their properties, namely the 
amplitude, the frequency and the degree of their coupling, change during memory processes; 
moreover, they are predictive of learning performance (Lisman and Jensen 2013). 
Several brain oscillations have been shown to interact, a phenomenon known as cross-
frequency coupling (CFC) (Canolty and Knight 2010). One particular type of interaction consists 
in the phase of a slower oscillation modulating the amplitude of a faster one, hence the name 
phase-amplitude CFC (PAC). The PAC of theta on gamma oscillations in the hippocampus has 
drawn a growing interest since it has proven to be a physiological feature remarkably suited for 
predicting memory performance (Axmacher et al. 2010; Tort et al. 2009). Most notably, theta-
gamma decoupling in the hippocampus impairs memory performance (Shirvalkar, Rapp, Shapiro 
2010). 
Further, a characteristic of brain electrophysiological signals is the “1/f” behavior of the 
frequency-domain power spectrum, meaning that the amplitude of each frequency component 
decays as a function of the frequency. Along with other features, the steepness of the decay has 
recently been shown to be informative about network activity. 
At present, there are no therapies to reliably revert or stop AD. A biomarker (or a combination 
of biomarkers) for a non-invasive early diagnosis of the pathology – i.e. before the emergence 
of the cognitive deficits – would improve the efficacy of current and future strategies to contrast 
the progression of the disease (Sperling and Johnson 2013a). 
Notwithstanding, FAD mutations of presenilin 1 (PS1) and, in particular of presenilin 2 (PS2) 
were shown to determine calcium (Ca2+) homeostasis impairment, a common feature in AD 
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(Zampese et al. 2011a). In particular, Ca2+ defects due to PS2-N141I appear to occur 
independently of Aβ load (Kipanyula et al. 2012). However, at the brain network level, outcomes 
due to the mutant PS2 have not been explored. 
The aims of this work were (i) the assessment of the effects of the PS2-N141I FAD mutation 
on the above-mentioned aspects of the hippocampal network activity and (ii) the identification 
of novel potential electrophysiological markers of the preclinical phase of AD. To these ends, we 
employed two FAD mouse models, PS2.30H and B6.152H, which express the human PS2-N141I 
mutation respectively alone or in combination with the human APP Swedish mutation (Ozmen 
et al. 2009; Richards et al. 2003). 
We investigated the local field potential (LFP) signal in the dentate gyrus (DG) region of the 
hippocampus in the condition of urethane anesthesia. Through the exploitation of frequency 
and time-frequency methods, we extracted several signal features, including amplitude, spectral 
steepness and theta-higher frequencies PAC. The temporal evolution of these features was 
assessed by investigating three age points, namely 3, 6 and 12 months. Additionally, we 
characterized our transgenic lines for three known molecular and histological biomarker of the 
disease. We quantified the degree of Aβ42 load at each time point while the presence of amyloid 
plaques and astrogliosis was addressed at 3 and 6 months of age. 
At 6 months of age, we report a significant power increase of slow-gamma (SG, 25 – 40 Hz) 
and high-gamma (HG, 40 – 90 Hz) oscillations in the PS2.30H line and of beta (10 – 25 Hz) and 
SG oscillations in the B6.152H line. Gamma oscillations and, more generally, a broadband power 
increase are generated by local network activity and are linked to active computation (Buzsáki 
and Wang 2012). The enhancement of beta and gamma power that we observe in our models 
likely reflects neuronal hyperactivity, consistently with similar observations in both sporadic and 
familial AD as well as in several AD mouse models (Stargardt, Swaab, Bossers 2015). In our mouse 
lines, this is the first time that the condition of neural network hyperactivity is described, 
although in vitro neuronal Ca2+ hyperexcitability was previously reported (Kipanyula et al. 2012). 
In B6.152H mice, hyperactivity was timed with the appearance of amyloid plaques and 
astrogliosis, whereas in PS2.30H mice no molecular or histological biomarker significantly 
differed from the wt (wild-type) line at any investigated age. The observed hyperactivity is 
possibly due to the expression of the mutant PS2, rather than to the Aβ load which we probed 
to be profoundly different in the two AD mouse lines. 
Only in the B6.152H line we found a more complex pattern of alterations. In addition to the 
broadband power increase, we report an enhancement of theta-beta and -SG PAC in this line at 
6 months. Moreover, B6.152H mice displayed a steeper power spectrum slope compared to wt 
mice at 3 and 6 months of age. Both the overcoupling and the steeper spectral slope are 
ascribable to a condition of neuronal hyper-synchronicity, though with notable differences 
(Voytek and Knight 2015). Remarkably, we found that the difference between B6.152H and wt 
mice in terms of steepness was strongest at 3 months of age and diminished with ageing. 
Therefore, although further investigation will be required to validate this finding, hippocampal 
network hyper-synchronicity appears to be a promising early marker of the disease, at least in 
the context of a high Aβ load.  
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2 RIASSUNTO 
La malattia di Alzheimer (AD, Alzheimer’s disease) è una patologia neurodegenerativa che 
colpisce un numero crescente di anziani. E’ caratterizzata da progressivo indebolimento delle 
funzioni cognitive e della memoria ed è la causa più comune di demenza, essendo responsabile 
del 60 – 70 % dei casi al di sopra dei 65 anni (World Health Organization, 2015). 
I principali elementi neuropatologici caratteristici della malattia sono la deposizione di 
ammassi neurofibrillari e placche senili, in primis in ippocampo, corteccia entorinale e 
neocorteccia, e una diffusa perdita di neuroni. 
L’AD si divide nelle forme sporadica e familiare (FAD, familial AD). La FAD è causata da 
mutazioni ad alto grado di penetranza a carico di tre geni coinvolti nel metabolismo della β-
amiloide (Aβ, amyloid-β): Aβ precursor protein (APP), presenilin1 (PSEN1) e presenilin2 (PSEN2) 
(Bertram and Tanzi 2011). 
Si ritiene che i primi cambiamenti patologici abbiano luogo nella formazione ippocampale e 
nella corteccia entorinale (Squire, Stark, Clark 2004). Queste regioni fanno parte del lobo medio-
temporale e sono fondamentali per la codifica di nuovi ricordi, così come per la fissazione di 
quelli recenti. Esse, inoltre, rientrano tra i primi bersagli della malattia in termini di alterazioni 
istologiche e neuro-fisiologiche; queste ultime correlano bene con i deficit mnemonici e sono 
considerate sintomi precoci della malattia (Sperling, Mormino, Johnson 2014; Squire, Stark, Clark 
2004). 
In ippocampo l’attività di network più evidente è data dalle oscillazioni dei field potentials nelle 
bande di frequenza theta (4 – 12 Hz) e gamma (30 – 100 Hz). Si ritiene che le oscillazioni theta e 
gamma giochino un ruolo centrale nei processi di memoria, in quanto le loro proprietà, ovvero 
l’ampiezza, la frequenza e il loro grado di accoppiamento, cambiano durante i processi 
mnemonici; inoltre, esse sono predittive della prestazione di apprendimento (Lisman and Jensen 
2013). 
E’ dimostrato che molte oscillazioni cerebrali interagiscono tra di loro, un fenomeno noto 
come cross-frequency coupling (CFC) (Canolty and Knight 2010). Una particolare tipologia di 
interazione consiste nella modulazione esercitata dalla fase di un’oscillazione più lenta 
sull’ampiezza di un’altra più veloce, da cui il nome CFC fase-ampiezza (PAC, phase-amplitude 
CFC). In ippocampo, il PAC delle oscillazioni theta sulle gamma ha attratto un crescente interesse, 
in virtù del fatto che ha dato prova di essere un aspetto fisiologico notevolmente adeguato per 
predire la prestazione mnemonica (Axmacher et al. 2010; Tort et al. 2009). In particolare, la 
perdita di coupling in ippocampo compromette il processo di apprendimento (Shirvalkar, Rapp, 
Shapiro 2010). 
Inoltre, una caratteristica dei segnali elettrofisiologici cerebrali è il comportamento “1/f” dello 
spettro di potenza nel dominio della frequenza, nel senso che l’ampiezza di ogni componente in 
frequenza decade in funzione della frequenza. Assieme ad altre caratteristiche, la rapidità di 
decadimento dello spettro di potenza (steepness), misurata come pendenza della funzione in 
una rappresentazione semilogaritmica, si è rivelata particolarmente informativa dell’attività di 
network. 
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Allo stato attuale, non esistono terapie efficaci per arrestare o far regredire l’AD. Un marcatore 
(o una combinazione di marcatori) per una diagnosi precoce non invasiva della patologia – cioè 
prima della comparsa dei deficit cognitivi – migliorerebbe l'efficacia delle strategie attuali e 
future per contrastare la progressione della malattia (Sperling and Johnson 2013a). 
Inoltre, è stato provato che le mutazioni FAD della presenilina 1 (PS1) e della presenilina 2 
(PS2) sono in grado di alterare l’omeostasi del calcio (Ca2+) intracellulare, una caratteristica 
comune nell’AD (Zampese et al. 2011a). Recentemente, è stato poi dimostrato che gli effetti 
della PS2-N141I sull’omeostasi del Ca2+ sono precoci ed indipendenti dai livelli di Aβ (Kipanyula 
et al. 2012; Zampese et al. 2011a) Tuttavia, gli effetti della PS2 mutata a livello del network 
cerebrale non sono stati ancora esplorati. 
Gli obiettivi di questo lavoro erano (i) la valutazione degli effetti della mutazione FAD PS2-
N141I sugli aspetti sopracitati dell’attività di rete ippocampale e (ii) l'identificazione di nuovi 
potenziali marcatori elettrofisiologici della fase preclinica dell’AD. A tal fine, abbiamo impiegato 
due modelli murini di FAD, PS2.30H e B6.152H, che esprimono la mutazione umana PS2-N141I, 
rispettivamente da sola o in combinazione con la mutazione Svedese dell’APP umana (Ozmen et 
al. 2009; Richards et al. 2003). 
Abbiamo studiato il local field potential (LFP) nella regione del giro dentato (DG, dentate gyrus) 
in ippocampo, nella condizione di anestesia con uretano. Attraverso metodi di analisi in 
frequenza e tempo-frequenza, abbiamo estratto diverse caratteristiche del segnale, tra cui 
l’ampiezza, la pendenza spettrale e il PAC tra oscillazioni theta e a frequenze maggiori. 
L'evoluzione temporale di queste caratteristiche è stata valutata analizzando tre età, ovvero 3, 
6 e 12 mesi. Inoltre, abbiamo caratterizzato le nostre linee transgeniche per tre noti marker 
molecolari ed istologici della malattia. Abbiamo quantificato il livello di Aβ42 ad ogni punto 
temporale, mentre la presenza di placche amiloidi e di astrogliosi è stata investigata a 3 e 6 mesi 
di età. 
A 6 mesi di età, riportiamo un significativo aumento della potenza delle oscillazioni slow-
gamma (SG, 25 - 40 Hz) e high-gamma (HG, 40 - 90 Hz) nella linea PS2.30H e delle oscillazioni 
beta (10 - 25 Hz) e SG nella linea B6.152H. Le oscillazioni gamma e, più in generale, un aumento 
di potenza ad ampio spettro, sono generate dall’attività del network locale e riflettono processi 
di computazione attiva (Buzsáki and Wang 2012). L’aumento della potenza nelle oscillazioni beta 
e gamma che osserviamo nei nostri modelli riflette, probabilmente, iperattività neuronale, 
coerentemente con osservazioni simili riportate nelle forme sia sporadica che familiare dell’AD, 
così come in diversi modelli murini di AD (Stargardt, Swaab, Bossers 2015). Nelle nostre linee, 
questa è la prima volta che la condizione di iperattività neurale di network è descritta, anche se 
in vitro era stata precedentemente riportata ipereccitabilità neuronale basata sul Ca2+ (Kipanyula 
et al. 2012). Nei topi B6.152H, l’iperattività coincide temporalmente con la comparsa delle 
placche amiloidi e dell’astrogliosi, mentre nei topi PS2.30H nessun marcatore molecolare o 
istologico risulta significativamente diverso dalla linea wt (wild-type) a qualunque delle età 
indagate. L'iperattività osservata è probabilmente dovuta all'espressione della PS2 mutata, 
piuttosto che al livello di Aβ, il quale si è rivelato essere profondamente diverso nelle nostre due 
linee modello dell’AD. 
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Solo nella linea B6.152H abbiamo trovato un pattern più complesso di alterazioni. Oltre 
all’aumento di potenza ad ampio spettro, riportiamo un incremento del PAC tra oscillazioni theta 
e beta e tra theta e SG in questa linea a 6 mesi. Inoltre, i topi B6.152H mostrano una forte 
pendenza del power spectrum rispetto ai topi wt a 3 e 6 mesi di età. Sia l’overcoupling che 
l’incremento della pendenza spettrale sono riconducibili ad una condizione di iper-sincronicità 
neuronale, anche se con differenze importanti (Voytek and Knight 2015). È da notare che la 
differenza tra topi B6.152H e wt in termini di pendenza spettrale è più marcata a 3 mesi di età e 
diminuisce con l'invecchiamento. Pertanto, anche se ulteriori indagini saranno necessarie per 
convalidare questa osservazione, l’ipersincronicità del network ippocampale sembra essere un 
promettente marcatore precoce della malattia, almeno nel contesto di alti livelli di Aβ. 
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3 INTRODUCTION 
The study of the brain encompasses multiple levels, ranging from the molecular and 
biophysical mechanisms underlying single neurons function to the complex web of their 
interactions that drives cognition and consciousness. Importantly, brain is a complex system, 
which basically means (i) that all the different levels organize in a hierarchical fashion, where 
each-level behavior is molded from the activity of both the higher and the lower level and (ii) 
that the qualities of the activity at a given level do not merely result from the sum of the 
properties of the basic constituents of that level but also emerge as novelties from the 
interaction among them. From this perspective, brain functioning has necessarily to be 
addressed at multiple scales. For instance, we cannot fully understand cognition by only 
considering the operation of single neurons and their connections. Rather, we need to further 
look at neuronal network activity as a whole. 
In particular, a number of neurological disorders, including AD, Parkinson’s disease, 
schizophrenia, epilepsy and autism, are associated with various forms of cognitive impairment 
and, historically, their pathophysiology has been studied focusing on molecular, cellular and 
pharmacologic aspects. 
Only recently, the fast development and improvement of techniques that allow the 
investigation of brain at a multi-scale level, on one hand, and the enrichment of the tool-box for 
signal processing and analysis on the other, have provided an unprecedented understanding of 
neuronal networks. This permits to investigate the functional network alterations that occur in 
neurological disorders, which represents a mesoscale bridging between the molecular/cellular 
aspects of the disorders and their effects on cognition. 
In the introduction, we first provide an overview of the techniques for recording or imaging 
neuronal network activity in vivo as well as the information that is obtainable from such data. 
Next, we briefly present the hippocampus, the brain structure on which the present study is 
focused. Finally, we describe the AD, its pathological as well as diagnostic aspects and some of 
the major recent findings regarding network alterations in the disease. 
3.1 FUNCTIONAL ACTIVITY OF THE BRAIN 
3.1.1 Neural activity recording 
Ideally, in order to investigate brain functioning, it should be possible to simultaneously 
assess neuronal activity at all spatial scales and with sufficient temporal resolution to adequately 
describe the fastest events. Unfortunately, none of the available technologies is able to 
simultaneously record the activity of a large number of neurons at the single-cell level and in the 
milliseconds timescale, as it is required for describing the action potentials (AP). Likewise, none 
of them is capable to continuously scale across all the different levels. All the approaches that 
are summarized here are a compromise between spatial and temporal resolution and each of 
them has advantages as well as limitations in addressing different aspects of brain activity. 
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The most direct and detailed way to gather information about brain functioning is the 
recording of the intracellular electrical activity of single neurons. The technique of choice for 
performing this task is the patch-clamp, where a glass pipette containing the recording electrode 
is brought in very tight contact with the cell membrane and the patch of membrane under the 
contact area is torn so that the electrode is in contact with the intracellular domain. The patch-
clamping technique offers unparalleled spatial and temporal detail, however it is only exploitable 
for recording from few cells at the same time. Hence, its usage for the investigation of neuronal 
networks is often very limited and the technique is generally confined to the study of cellular 
and sub-cellular dynamics. Nevertheless, accumulating findings proved patch-clamp useful at 
the network scale when combined with other higher level approaches. 
Neuronal electric activity – be it action potentials (APs), subthreshold fluctuations, or post-
synaptic potentials (PSP) – consists in continuous changes of transmembrane potential. Such 
changes rely on current flow across the membrane and, thus, they mobilize ions to and/or from 
the extracellular milieu. Therefore, at this level, the electric potential recorded at a given point 
results from the linear sum of the electric fields generated by the ongoing activity of all the 
neurons surrounding the recording site. This type of recording is referred to as LFP, emphasizing 
the “local” nature of the acquired signal. Indeed, extracellular ionic current propagation is 
attenuated as a function of the distance from the source, owing to the resistance of the medium 
and the presence of cell membranes on the path. Importantly, fast events are more affected 
than slow events. It follows that, for instance, a PSP-induced current can travel further with 
respect to an AP-induced one. 
Highly sensitive electrodes placed on the scalp of a subject exploit the same principle of the 
LFP as they detect the electric fields generated by the sum of the neuronal activities in a very 
large volume. This technique is called electroencephalography (EEG) and it allows the non-
invasive simultaneous recording from a number of sites above the brain surface. The recorded 
signal is, however, affected by the distortion and the attenuation exerted by the meninges, the 
skull and the scalp as the current travels through them. The temporal resolution is ideally the 
same as in the intracellular recording but in practice only relatively slow activities reach the scalp 
electrodes.  
Somehow in between the LFP and the EEG in terms of spatial resolution and invasiveness it 
is the electrocorticography (ECoG), which consists in the subdural application of a grid of 
electrodes over the brain, in direct contact with the cerebral cortex. The advantage with respect 
to the EEG is a large increase in spatial resolution and signal amplitude as well as a strong 
decrease of muscle artifacts. Nevertheless, the ECoG signal is largely confined to the cortex and 
this technique can hardly be exploited for investigating deep brain dynamics. Yet, the most 
important drawback of ECoG is invasiveness: although it is less harmful to the brain when 
compared to implanting LFP recording electrodes, the procedure requires a surgical operation, 
hindering its usage in humans for solely research purposes. 
Owing to historical reasons, it is conventional the usage of the EEG, ECoG and LFP terms as I 
described above. In this work, we always refer to them accordingly. However, it is noteworthy 
that a strict definition of the EEG signal would trace it as a synonymous of extracellular-
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recording. As such, the EEG notion would encompass both the ECoG and the LFP signals and, 
indeed, these latter are sometimes referred to as depth, micro- or intracranial EEG. 
One of the fundamental principles in electromagnetism is the reciprocal behavior of electric 
and magnetic fields. It follows that it is possible to exploit the variations of magnetic field to infer 
the voltage changes due to neuronal activity. This is, indeed, the underlying principle of the 
magnetoencephalography (MEG). As in the EEG, MEG sensors are capable of monitoring brain 
signals from outside the head, ensuring non-invasiveness. In this case, sensors are 
superconducting quantum interference device (SQUID) which operate at -270 °C in order to 
detect the very weak magnetic signals that arise from the brain. Contrarily to electricity, 
magnetic signal propagation is not hindered by air, thus, MEG sensors do not even need to be 
attached to the subject’s head. Yet, the major advantage of the MEG is the fact that the magnetic 
signal is spared from any distortion as it crosses the overlaying tissues, which is beneficial mainly 
to spatial resolution. 
A more indirect approach is called functional magnetic resonance imaging (fMRI). This 
technique images the brain and returns a map of the active areas at a given moment. The 
principles and the assumptions on which fMRI is based are several. A strong magnetic field is 
applied to the subject’s body so that the spin of every atom becomes aligned to the magnetic 
field. Then, a radio frequency (RF) pulse at the frequency specific for the atom of interest is 
applied. Consequently, the atom-containing molecules are perturbed from the preferred 
alignment and, once the RF pulse ceases, the atoms realign with the magnetic field releasing 
energy. This latter is detected from sensors placed around the head. In magnetic resonance 
imaging (MRI) the target atom is hydrogen and the procedure yields contrasted anatomical 
images, useful for structural investigation of the brain. The main type of fMRI, instead, targets 
hemoglobin. In particular, it exploits (i) the reduced magnetic susceptibility of oxygenated versus 
deoxygenated hemoglobin and (ii) the hemodynamic response – i.e. the modulation of blood 
and oxygen supply depending on the energetic demand in a given region. Accordingly, it is called 
blood oxygen level-dependent (BOLD) fMRI. Basically, when a neuronal ensemble becomes 
active, it triggers blood supply enhancement to support the increased energy consumption 
(functional hyperemia). Consequently, the relative area results enriched in oxygenated 
hemoglobin and the changing is monitored as a variation of magnetic resonance. When 
statistically significant, the changing is reported on the map of active areas. 
Concerning the spatial resolution, the fMRI offers remarkably detailed information while 
providing a whole brain image, thus empowering to investigate brain function during cognitive 
tasks as well as while in “resting state”. However, the two major drawbacks of this technique 
arise from its indirect nature: (i) the temporal resolution mainly depends on the physiological 
kinetics that regulates oxygenated blood recruitment. This type of kinetics is on the order of 
seconds; (ii) the blood supply to a given area increases in response to whatsoever neuronal 
activity. Hence, the exact nature of the activity responsible for the increased energetic demand 
– whether it is e.g. neuronal firing or synaptic activity – remains elusive and can only be inferred. 
Positron emission tomography (PET) is yet another advanced imaging method capable of 
visualizing brain function. The technique roughly consists in the injection or inhalation of a 
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biologically active molecule carrying a radiolabeled compound. As this latter decays, positrons 
are emitted and, indirectly, gamma rays are produced and can be detected by the ring sensor of 
the PET scanner.  Therefore, it is possible to monitor the dynamics of the tagged biological 
molecule, although with lower temporal and spatial resolution than in fMRI. Fluorodeoxyglucose 
(FDG), an analogue of glucose, is often used as tracer, providing spatial and temporal information 
on glucose uptake and thus, similarly to BOLD-fMRI, on the metabolic activity in a given area. 
As a final comment, we wish to underlie that, despite its usage in clinical and research 
settings dating back to 1929 – when Hans Berger first described the EEG – the extracellular 
electrophysiology is still a developing field, in particular concerning signal analysis. For decades, 
EEG recordings were investigated by sole ocular assessment. Only recently, the advent of a 
handful of data processing tools, in conjunction with the development of ever-faster computers 
empowering to routinely exploit them, has opened new avenues for neural physiology and 
pathophysiology understanding.  
(Adeli and Ghosh-Dastidar 2010; Buzsaki 2006a; Buzsáki, Anastassiou, Koch 2012; Sporns 2011) 
3.1.2 Neuronal networks and brain oscillations 
What bridges between the microscale of single neurons and synapses activity and the 
macroscale of cognition and consciousness is the integrated connection of the units into 
networks that dynamically organize on hierarchical levels. As described in the previous 
paragraph, different techniques are better suited for investigating brain activity and functioning 
depending on the targeted level of organization (Sporns 2011).  
The emergent feature of single neurons is the AP. Various types of membrane ionic 
conductance feature distinct biophysical properties, accounting for either specific or nonspecific 
ionic flow and conditions and parameters of the flow. Yet, particular assortments of ion channels 
give rise to the autocatalytic all-or-none phenomenon, the AP, suited for reliably binary encoding 
and information transmitting. At the opposite extreme, the richness of psychological categories 
(James 1890), including perceptions and emotions, is the grand emergent feature of the cerebral 
cortex working as a whole. 
From an intermediate magnification, one of the most striking phenomena that spontaneously 
emerges is rhythmicity, the result of integrated network activity of neurons and astrocytes, that 
is easily observable by means of extracellular electric signal recording. 
The first brain electrophysiological oscillatory pattern was described in 1929 by Hans Berger 
(Berger 1929). He observed that, if a subject was in a relaxed state and with eyes closed, a 
marked oscillation of the EEG signal appeared, in particular in the occipital region. The oscillation 
had a period of approximately 100 ms – 10 Hz – and Berger called it “alpha”. In addition, when 
the subject opened the eyes, the alpha rhythm disappeared in favor of a faster, smaller 
amplitude one, that he named “beta”. 
Since Berger’s seminal findings, the oscillatory features of the extracellular brain signal have 
been extensively studied (Steriade et al. 1990). Several other rhythms were described in distinct 
areas as well as during various cognitive states and were generally named with Greek letters. 
These include delta (or slow waves), theta, spindles and gamma. They added on Berger’s alpha 
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and beta. In 1974, the oscillatory classes where classified in a taxonomy mainly intended for 
clinical purposes (International Federation of Societies for Electroencephalography and Clinical 
Neurophysiology 1974). 
Delta oscillations have a frequency range of 0.5-4 Hz and are predominant during deep sleep 
phases. Theta rhythms are prominent in the hippocampal formation and emerge during rapid 
eye movement (REM) sleep as well as in correspondence with various exploratory activities in 
the awake animal (Buzsáki 2002). Although clinical classification of theta oscillations defines their 
range as of 4-8 Hz (International Federation of Societies for Electroencephalography and Clinical 
Neurophysiology 1974), this rhythm is the most variable across species in terms of frequency 
(Buzsáki, Logothetis, Singer 2013). Alpha waves (8-13 Hz) are present during wakefulness 
particularly over the occipital cortex and increase during attention tasks (Ray and Cole 1985). 
Spindles are waxing and waning oscillations with a frequency between 7 and 14 Hz, occurring 
every 5-10 sec and lasting 1.5-2 sec. Differently from alpha waves, spindles mark the light stage 
of sleep. In particular, they were characterized in the transition from waking to sleep (Steriade 
and Deschenes 1984). Beta oscillation occur in the range of 12-30 Hz and are generally 
associated with active thinking and, in particular when recorded over the motor areas, with 
voluntary movement suppression. Gamma rhythm encompasses a broad range of frequencies, 
from 30 to 90 Hz in the traditional taxonomy. While it is found ubiquitously in the cerebral cortex, 
on the other hand it is a local network rhythm. Yet, notably, distant networks can display 
synchronized gamma oscillations under certain circumstances (Buzsáki and Wang 2012). 
The characteristics of the oscillatory extracellular signal are determined by the proportional 
contribution of all the ongoing cellular electric activities, including APs, PSPs, subthreshold 
fluctuations, as well as on the properties of the tissue. Nevertheless, brain oscillations should 
not be diminished to epiphenomena or poorly revolved approximations of the overall neuronal 
activity. On the contrary, the rhythmic oscillation, in turn, provides “contextual constraints”, 
influencing single neuron activity. Network oscillations bias neuron membrane potential and, 
thus, favors or opposes firing in response to synaptic input, synchronizes neurons into 
assemblies and modulate synaptic plasticity (Buzsáki and Draguhn 2004). 
3.2 THE HIPPOCAMPAL FORMATION 
The hippocampal formation (HF), often simply called “hippocampus”, is a medial temporal 
lobe structure, located under the cerebral cortex. Its general definition includes the territories 
of DG, Cornu Ammonis (CA) – or hippocampus proper – and subiculum on the basis of the three 
layered architecture that they share. This is the HF designation that will be used here. Yet, the 
denomination ”hippocampal formation” is sometimes extended to the presubiculum, the 
parasubiculum and the entorhinal cortex (EC), in light of the involvement of all these districts in 
the declarative memory function. Indeed, although a definitive answer in regard to the function 
of the hippocampus has not yet emerged, a large deal of evidence indicates that the medial 
temporal lobe in general, and the HF in particular, are essential brain components for 
anterograde declarative (i.e., consciously recallable) memory formation as well as for 
consolidating information from working to long-term memory (Andersen et al. 2006; Squire, 
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Stark, Clark 2004). Clinical investigation of patients with brain damage against the hippocampal 
region, including the famous cases of H.M. (temporal lobe surgery), N.A. (accident) and R.B. 
(ischemia), report the impairment of anterograde declarative memories formation as a common 
trait along with an intact ability of procedural (or non-declarative) memory learning (Purves 
2004). On the other hand, studies based on fMRI in humans show that the formation of new 
episodic memory is associated with DG, CA2 and CA3 activation, though this is not the case 
during memory retrieval (Kirwan and Stark 2004; Zeineh et al. 2003). 
Nevertheless, it should be noted that the hippocampus has also been implicated in other 
functions, including processing of olfactory information (Kay and Lazzara 2010; Vanderwolf 
2001), spatial navigation (Craig and McBain 2015) and time-space codification (Nielson et al. 
2015). Therefore, the complete picture of hippocampal function is likely to be complex. L. R. 
Squire broadly defined the hippocampus function as follows: “The hippocampus is important in 
both spatial and nonspatial tasks where new information must be acquired and associated in 
ways that allow it to be used flexibly to guide behavior” (Squire, Stark, Clark 2004). 
Figure 1, reports the main connectivity of the HF. The circuitry in largely, yet not only, 
unidirectional, with the EC serving as a major input provider. Neurons in the superficial layers II 
and III of the EC project, respectively, to the DG and CA3 and to the CA1 and subiculum regions. 
The granule cells of the DG are the main target of the EC layer II axons, these latter forming the 
so-called “performant-path”. DG granule cells, in turn, send axons (or “mossy fibers”) principally 
to the CA3 region, where the main recipient are the pyramidal cells. The outbound projections 
of CA3 pyramidal cells form the Schaffer collaterals which make synapses onto the pyramidal 
cells in the CA2 and CA1 regions. CA1 pyramidal cells project axons to the subiculum and, finally, 
this latter jointly with CA1 form the major output of the HF by sending axons back to the V layer 
of entorhinal cortex. Also, while the principal target of the cortical projections of the subiculum 
is the EC, the former constitutes the major output to the subcortical regions. (Andersen et al. 
2006). Only the excitatory glutamatergic connections compose the hippocampal connectivity 
just described. Yet, in addition to the EC glutamatergic input, another widely studied drive to the 
 
Figure 1. Hippocampal formation and main circuitry. The scheme describes the largely unidirectional connectivity in the 
hippocampus. Neurons in the superficial layers of the EC, which is the principal communication node between hippocampus 
and cortex, project to CA3 the DG through the perforant path. DG neurons form the mossy fibers and synapse onto CA3 
neurons. Neurons in the CA3 subfield send axons to CA1 forming the Shaffer collaterals. CA1 neurons project to the 
subiculum and the deep layers of the EC. Efferences of the subiculum form synapses in the deep layers of the EC and form 
the principal output to the subcortical regions. Image adapted from (Andersen et al. 2006).  
 
 
Hippocampal formation and main circuitry. The scheme describes the largely unidirectional connectivity in the hippocampus. 
Neurons in the superficial layers of the EC, which is the principal communication node between hippocampus and cortex, 
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HF that we wish to mention is the cholinergic/GABAergic input from the medial septal nucleus 
and the nucleus of the diagonal band of Broca (MS-DBB) through the fimbria-fornix pathway 
onto the DG region. These input connections in the DG arising from this pathway are few 
compared to the performant path, nonetheless they play an important role in the generation of 
hippocampal theta oscillation (Andersen et al. 2006). 
3.2.1 Theta-Gamma oscillations and memory 
Theta and gamma oscillations are the principal oscillatory activities occurring in the 
hippocampus under physiological conditions (Bragin et al. 1995; Vanderwolf 1969). Both 
rhythms have been implicated in anterograde memory formation, working memory functioning 
and short-term memory retrieval (Lisman and Jensen 2013). In particular, theta power increased 
in successful memory encoding and in working memory retrieval (Kahana, Seelig, Madsen 2001; 
Lega, Jacobs, Kahana 2012) as well as during navigation (Vanderwolf 1969). In addition, the 
phase of the theta was shown to influence synaptic plasticity, with long-term potentiation (LTP) 
favored at the peak of the wave and depotentiation favored at the trough (Holscher, Anwyl, 
Rowan 1997). On the other hand, gamma power increases during memory encoding and 
correlates with successful subsequent recall (Sederberg et al. 2007a; Sederberg et al. 2007b). 
Furthermore, gamma power both remains high during the holding period in working memory 
tasks and positively correlates with memory load (Van Vugt et al. 2010). 
Most notably, besides being present during memory storage, theta and gamma changes were 
capable to predict learning (Fell et al. 2011; Sederberg et al. 2007b) and retrieval performance 
(Lega, Jacobs, Kahana 2012). 
Several brain oscillations have been shown to interact, a phenomenon known as CFC (Canolty 
and Knight 2010). The most commonly studied type of interaction consists in the phase of a 
slower oscillation modulating the amplitude of a faster one, hence the name PAC. The PAC of 
theta on gamma oscillation in the hippocampus has drawn a growing interest since it has proven 
to be a physiological feature remarkably suited for predicting memory formation (Axmacher et 
al. 2010; Lega et al. 2016) and recall (Shirvalkar, Rapp, Shapiro 2010). Most notably, theta-
gamma decoupling in the hippocampus impairs memory performance (Shirvalkar, Rapp, Shapiro 
2010). In this context, theta-gamma PAC is regarded as a bridge between local microscale 
neuronal ensembles and the systems-level macroscale network, allowing for dynamic network 
communication (Voytek and Knight 2015). 
While the mechanisms governing the generation of APs are well understood, the dynamics at 
the basis of extracellular field oscillations have only partially been unveiled. Hippocampal theta 
rhythm is considered as a “consortium of mechanisms” (Buzsáki 2002), since it springs from the 
conjunction of intracellular and synaptic properties. Hippocampal theta depends on (i) intrinsic 
resonance properties of pyramidal neurons, (ii) interneurons-mediated inhibitory feedback and 
(iii) cholinergic inputs from the MS-DBB (Buzsáki 2002). Indeed, while MS-DBB lesions both 
abrogate theta oscillations in the hippocampus and impair memory (Winson 1978), the 
administration of muscarinic agonists to MS-DBB increases theta power (Lawson and Bland 
1993) and favors learning (Markowska, Olton, Givens 1995). More recently, theta rhythm was 
alternatively proposed to be primarily relayed to the DG, in the HF, from the EC by means of 
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glutamatergic synaptic currents (Pernía-Andrade and Jonas 2014). Gamma oscillations, on the 
other hand, emerge as a result of the excitatory-inhibitory feedback connection between 
pyramidal cells and parvalbumin-expressing (PV) interneurons (Buzsáki and Wang 2012; Colgin 
and Moser 2010). 
3.3 ALZHEIMER’S DISEASE 
AD is an incurable neurodegenerative disease ultimately leading to death. It is the most 
common type of dementia (or major neurocognitive disorder) accounting for 60 to 70 % of the 
cases (World Health Organization, 2015). The Alzheimer’s Association estimates the 11 % of 
Americans aged 65 or older to be affected (Alzheimer's Association, 2015). AD is generally 
characterized by cognitive symptoms including memory loss, difficulty completing familiar tasks, 
confusion, decreased or poor judgement, changes in mood and personality (Alzheimer's 
Association, 2015). Moreover, AD is largely associated with two neuropathological elements: the 
extracellular accumulation of amyloid plaques and the intracellular aggregation of neurofibrillary 
tangles (Selkoe 1991). Yet, the correspondence is not always consistent. 
3.3.1 Historical background 
AD is named after Alois Alzheimer’s, who first described the pathology in his patient, Auguste 
Deter. He closely observed the clinical manifestations in her case for almost 5 years before she 
died and he investigated the neuropathology in her brain tissues after death. He reported 
progressive cognitive impairment – including reduced comprehension and memory – 
hallucinations, delusions and psychosocial incompetence along with the presence of evenly 
distributed miliary foci (later called senile plaques), neurofibrillary tangles and arteriosclerotic 
changes in the necroptic brain tissues (Alzheimer 1907; Maurer, Volk, Gerbaldo 1997). 
Several other cases (Alzheimer 1911; Fischer 1907; Perusini 1909) were described shortly after 
Alzheimer’s observations and AD started being considered a clinical-pathological entity, 
exhibiting a consistent correspondence between the clinical symptoms and histopathological 
traits, these latter in the form of senile plaques and neurofibrillary tangles. Although similar cases 
had been previously described in elderly people and acknowledged as senile dementia, Auguste 
D.’s relatively young age – 51 years at the time of her illness onset – was suggestive of a discrete 
disease, distinguishable from senile dementia occurring in the elders. This bias explains why AD 
was initially recognized as a rare presenile dementia (Ryan, Rossor, Fox 2015). Only several 
decades later, the continuum between AD and senile dementia became clearly apparent 
(Katzman 1976; Tomlinson, Blessed, Roth 1970). Finally, it was discovered that senile plaques 
derive from the extracellular deposition of Aβ protein (Glenner and Wong 1984) while 
intracellular aggregation of tau proteins is responsible for the neurofibrillary tangles (Goedert et 
al. 1988). 
3.3.2 AD clinical diagnosis 
The new unified picture paved the way to the definition of novel comprehensive clinical 
criteria (McKhann et al. 1984) for the diagnosis of AD that have since been in use (American 
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Psychiatric Association 2013). Probable AD is diagnosed when the following parameters are fully 
met: 
 Established dementia; 
 Deficits in at least two areas of cognition; 
 Progressive worsening of memory and other cognitive functions; 
 No disturbance of consciousness; 
 Onset between ages of 40 and 90; 
 Absence of systemic disorders. 
Definitive diagnose requires histopathologic evidence in addition to the abovementioned 
criteria. 
Although, there is no large consensus over the clinical stages of the disease, the American 
Psychiatric Association recognizes three levels of severity in AD, as any other dementia, that can 
be distinguished basing on the hindrance of daily living (American Psychiatric Association 2013): 
 Mild: difficulties with instrumental activities; 
 Moderate: difficulties with basic activities; 
 Severe: fully dependent on caregivers. 
Furthermore, the condition where a subject displays light but measurable cognitive decline, 
yet not satisfying the criteria for AD, has historically been called Mild Cognitive Impairment (MCI) 
(Petersen et al. 2001). MCI does not necessarily represent a prelude to AD, as only some 5 % of 
patients progress from MCI to AD each year. On the other hand, where the MCI involves memory 
problems - amnesic MCI (aMCI) - the risk of developing AD increases. For this reason, aMCI is 
sometimes referred to as preclinical AD or prodromal AD (Manly et al. 2008). 
Recently these criteria were revised in order to account for the more complex picture that 
has meanwhile emerged (Jack et al. 2011) and that we summarize in the next paragraphs. 
3.3.3 Genetics of AD 
Families presenting patterns of AD suggestive of dominant autosomal transmission have long 
been known (Ryan, Rossor, Fox 2015). Yet, only in 1991 a linkage analysis in one of those families 
identified, on chromosome 21, the first fully penetrant dominant gene: APP (Aβ precursor 
protein) (Goate et al. 1991). Two other genes, PSEN1 (presenilin 1) and PSEN2 (presenilin 2), 
were discovered few years later on chromosome 14 and 1, respectively (Rogaev et al. 1995). 
Mutations in one of these three genes invariably cause the disease – with the notable 
exception of two APP mutations providing protection against AD (Di Fede et al. 2009; Jonsson et 
al. 2012) – and account for the large majority of cases of autosomal-dominant inheritance. 
Additionally, two recessive pathological APP mutations are known (Di Fede et al. 2009; 
Tomiyama et al. 2008). The condition is known as FAD, with PSEN1 mutations being responsible 
for most of FAD cases (Ryan, Rossor, Fox 2015) and  PSEN1 and PSEN2 together accounting for 
90% of FAD case (Honarnejad and Herms 2012). 
 
15 
While AD-linked mutations in APP and PSENs account for the full penetrance of FAD, other 
genes were shown to be involved in modulating the probability of developing the disease, 
without necessarily determining it (Bertram and Tanzi 2011; Guerreiro and Hardy 2014). The 
strongest described genetic risk factor was identified in APOE (Apolipoprotein E) epsilon allele 
(ApoE4), which increase one’s odds to develop AD by a 3- or 8- to 12-fold factor, depending on 
number of copies (Saunders et al. 1993). 
Notably, FAD causing genes are associated with a form of AD that develops particularly early 
in life, generally in the late 40ies of an affected person but it could emerge as soon as in the 
30ies or even late 20ies. This form of AD has been therefore named early-onset AD (EOAD) in 
distinction to the more common late-onset AD (LOAD). 
Nevertheless, subjects carrying FAD genes sometimes develop the disease past the age 65 
and, on the contrary, EOAD can be diagnosed in patients that do not present a strong AD-linked 
genetic background. Hence, while these categories are useful for practical research and clinical 
purposes, it important to note that AD exists in a continuum (Alzheimer's Association, 2015). 
As a curiosity, we report that, after the rediscovery Auguste D.’s brain sections in Frankfurt 
(Graeber et al. 1998), the genetic basis of her EOAD was recently controversially debated. A first 
study reported a nucleotide substitution in exon 6 of PSEN1, possibly responsible for the EOAD 
(Muller, Winter, Graeber 2013), yet the conclusions were questioned by a following work that 
could not replicate the results (Rupp et al. 2014). 
3.3.4 Pathogenesis 
APP, PSENs and APOE all code for proteins involved in the metabolism of Aβ (Hardy and 
Selkoe 2002). This latter is a 38-43 aminoacids-long peptide that, within the pathology, serves 
as building block of senile plaques (Glenner and Wong 1984; Masters et al. 1985), also called 
“amyloid” (starch-like) plaques. The two major isoforms of Aβ are Aβ40 and Aβ42, the latter being 
the most prone to aggregate. 
APP encodes for Aβ precursor protein (APP) (Kang et al. 1987) which is a plasma membrane 
transmembrane glycoprotein. The sequential cleavage of APP performed by two proteolic 
enzymes, β-secretase first and then γ-secretase, determines the production of Aβ (see Figure 2). 
In particular, γ-secretase is a multimeric enzyme whose catalytic core is provided by presenilin. 
This exists in two isoforms, PS1 and PS2, which are encoded by PSEN1 and PSEN2, respectively 
(Selkoe and Wolfe 2007). Alternatively, APP can be also cleaved by α-secretase at a different site 
generating a non-amyloidogenic peptide. 
In 1992, the notion that Aβ is the molecular constituent of senile plaques, joint with the 
recent discovery of APP mutations being causative of AD, laid the foundation of the seminal 
amyloid cascade hypothesis (Hardy and Higgins 1992). The hypothesis posits that Aβ is the 
initiator, “the culprit”, of the series of events leading to AD, including neurofibrillary tangles 
formation. 
At the time of the hypothesis formulation, Aβ was thought to be noxious to the brain in the 
form of amyloid plaques. However, several lines of evidence oppose this view. First, 
neurofibrillary tangles seem to appear earlier than amyloid plaques, as suggested by the 
pioneering work of Braak and Braak (Braak and Braak 1998). Second, cognitive decline does not 
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correlate with plaques deposition (Terry et al. 1991) – most strikingly, distributed plaques were 
reported in a subset of nondemented elders as well as many AD patients were found not to 
present plaques at a post mortem analysis (Price and Morris 1999). Third, neurological deficits 
independent of plaques were reported in mouse models (Lesné, Kotilinek, Ashe 2008). 
 The Aβ forms that are attracting the most interest for their potential responsibility in causing 
AD are Aβ42 monomers and oligomers. The latter were shown to be increased in AD patients and 
to be the earliest component of amyloid plaques (Younkin 1995). In particular, the relative Aβ42 
concentration in relation to the Aβ40 one – i.e. the Aβ42/ Aβ40 ratio – is increased in PSEN-based 
models of FAD in vitro (Bentahir et al. 2006). Accordingly, AD-causing mutations in APP and 
PSENs affect APP processing and increase either the Aβ42  level or simply the Aβ42/ Aβ40 ratio 
(Bentahir et al. 2006; Suzuki et al. 1994). On the other hand, Aβ aggregation, before ending in 
insoluble plaques, determines the formation of a wealth of intermediate soluble oligomers 
(Aβo). Aβo were observed in human AD brains (Shankar et al. 2008) as well as in AD models 
(Lesné et al. 2006) and, notably, they affect synaptic plasticity, dendritic spine density and 
memory (Lesné et al. 2006; Shankar et al. 2008). 
In the past 24 years from the amyloid cascade formulation, the details of the hypothesis have 
been progressively readapted to account for the increasingly larger knowledge on the molecular, 
genetic and pathological aspects of the disease. Yet, the hypothesis has remained the best 
accepted model and has provided a valuable theoretical framework to research in the field. In 
the current formulation of the amyloid cascade hypothesis, Aβ42 peptides form progressively 
larger aggregates, from soluble Aβo to insoluble plaques. Aβ aggregates, especially soluble Aβo, 
 
Figure 2. APP processing. The scheme recapitulates the two processing pathways that APP can undertake. The sequential 
cleavage operated by the β- and then the γ-secretase constitutes the Aβ producing pathway, which potentially leads to Aβo 
and amyloid plaques aggregation. The APP intra-cellular domain (AICD) is also released as a result of γ-secretase cleavage. 
Conversely, APP cleavage performed by the α-secretase results in non-amyloidogenic APP fragments. Image adapted from 
(Gandy 2005). 
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cause oxidative injury, gliosis and Ca2+ 
dysregulation ultimately resulting in 
synaptic loss and neuronal death. 
Of note is the involvement in AD and 
pathological aging of alterations in Ca2+ 
homeostasis that was originally 
suggested by Khachaturian in the late ’80 
(Khachaturian 1987) and soon integrated 
in the amyloid cascade hypothesis (Hardy 
and Higgins 1992). The more recent 
discovery that presenilins (PSs) are not 
only involved in Aβ42  production but are 
also directly responsible of Ca2+ 
alterations at multiple levels, including 
endoplasmic reticulum (ER), 
mitochondria and plasma membrane, 
substantiates and widens the original 
version of the Ca2+ hypothesis of AD, that 
was simply based on Aβ-induced Ca2+ 
defects (Honarnejad and Herms 2012).  
Nowadays the amyloid cascade 
hypothesis is challenged because of a 
number of aspects that it fails to explain 
(Harrison and Owen 2016). Most notably, (i) biomarker studies suggest that about one third of 
elderly people without cognitive impairment show significant brain Aβ load; (ii) neurofibrillary 
tangles may appear earlier than amyloid plaques (Braak and Braak 1998; Price and Morris 1999); 
(iii) their topographic distribution differs from Aβ plaques deposition and neurodegenerative 
changes: neural loss is predominantly in the hippocampus and entorhinal cortex, whereas 
plaques are first found in frontal regions; (iv) clinical symptoms better correlate with tangles 
than Aβ burden; (v) Aβ42 toxicity has been largely observed in vitro, and, most frequently at Aβ 
concentrations order of magnitudes higher than those found in the pathophysiology of AD 
(Fedele et al. 2015).  
Yet, the strongest concern over the hypothesis probably arises from the failure of Aβ-
targeting trials (Herrup 2015). Though, it is also argued that the unsuccessful results of the trials 
do not necessary imply the hypothesis to be wrong. It might rather be that it has not been 
properly tested because of insufficient target engagement or because the drugs may have been 
administered too late in the disease process (Golde, Schneider, Koo 2011). 
AD pathology, additionally, includes the establishment of astrogliosis, a condition where 
astrocytes become reactive and release cytokines and other pro-inflammatory mediators, 
exerting a neuroinflammatory function (Steardo Jr et al. 2015). In this condition, astrocytes 
present a strong increase in the expression of glial fibrillary acidic protein (GFAP). Astrogliosis 
 
Figure 3 Effects of Aβ synaptic release. The illustration depicts the 
principal, yet not all, known pathways that are affected by Aβo at 
the postsynaptic level after its release from a presynaptic neuron. 
Image from (Agostini and Fasolato 2016). 
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generally precedes amyloid plaques deposition, though it is not clear at which stage its role in 
the development of the disease switches to disease advancing from being of benign defensive 
reaction. Nevertheless, astrogliosis has been proposed as a potential disease-modifying target, 
in light of the deleterious neurotoxic consequences of the sustained neuroinflammation arising 
from the self-perpetuating process of reactive gliosis (Rodríguez-Arellano et al. 2015; Steardo Jr 
et al. 2015). 
Recently, a new interesting model accounting for the observations here recapitulated was 
proposed (Puzzo et al. 2015). It is reasoned that Aβ loss of function could result in a feedback 
enhancement of the dysfunctional peptide. In turn, high levels of Aβ would cause the inhibition 
of alpha7 nicotinic acetylcholine receptors (a7-nAchRs) determining synaptic dysfunction. 
However, a weak point of this model is that it requires Aβ to be loss of function towards inhibiting 
itself expression but, at the same time, capable of inhibiting a7-nAchRs. Moreover, it forgets to 
consider the other recognized Aβ targets, among which the most studied are the glutamate 
receptors NMDAR and mGluR5 (Wang et al. 2015). 
Altogether, there is growing consensus that a reassessment of the framework is needed and 
that Aβ is unlikely to be the sole causative element of the disease (Herrup 2015). 
3.3.5 Presenilins and Ca2+ homeostasis 
PS1 and PS2 have become known for their role in Aβ processing, as the catalytic core of γ-
secretase (Selkoe and Wolfe 2007). Yet, while γ-secretase is also involved in the proteolysis of a 
handful of substrates other than APP, including Notch (Hass et al. 2009), on the other hand, PSs 
per se intervene in several cellular processes ranging from signal transduction to tau 
phosphorylation and Ca2+ homeostasis (Honarnejad and Herms 2012). 
As far as Ca2+ homeostasis is concerned, PSs are mainly implicated in ER Ca2+ signaling 
(Honarnejad and Herms 2012) and mitochondria-ER Ca2+ crosstalk (Zampese et al. 2011a). 
Notably, FAD-PS mutations, in vitro and in situ, enhance (Stutzmann et al. 2004) or reduce 
(Kipanyula et al. 2012) inositol trisphosphate receptor (IP3R)-evoked Ca2+ responses as well as 
they increased Ryanodine receptors (RyR) expression and, thus, RyR-mediated Ca2+ response to 
caffeine (Kipanyula et al. 2012; Stutzmann et al. 2006). In addition to regulating protein levels, 
PSs directly modulate RyR channel opening probability (Hayrapetyan et al. 2008), this feature 
possibly bridging between FAD-PS mutations and RyR-mediated Ca2+ release dysregulation. 
Finally, FAD-PS2 mutations decrease ER Ca2+ content by dampening SERCA activity and slightly 
increasing passive ER Ca2+ leak (Brunello et al. 2009). In addition, they also increase 
mitochondrial Ca2+ uptake by favoring closer ER-mitochondria contact sites (Kipanyula et al. 
2012). On the other hand, FAD-PS1 mutations cause ER Ca2+ overload by reducing ER Ca2+ leak 
thus indirectly favoring mitochondria Ca2+ uptake (Bezprozvanny 2009; Tu et al. 2006) but see 
(Shilling et al. 2012). 
How the altered ER Ca2+ content/release and increased mitochondrial Ca2+ uptake cause the 
neuronal Ca2+ hyperactivity observed in FAD models in vitro and in vivo (see Neural hyperactivity) 
has to be explained yet (Busche et al. 2008). 
It should be noted that, while PS1 and PS2 are highly homologue and share most of their 
known cellular functions (Honarnejad and Herms 2012; Lai et al. 2003), nevertheless several 
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important difference have been described, including (i) PS1 being a stronger Aβ producer and 
(ii) PS2, unlike PS1, being involved in the modulation of ER-mitochondria interaction (Shilling et 
al. 2012; Zampese et al. 2011a). 
3.3.6 Current trend in AD diagnosis criteria 
Since the definition of the still practiced criteria for AD diagnosis (McKhann et al. 1984), our 
knowledge on both the pathophysiology of AD, and the clinical manifestations that are timed to 
its progression, has largely increased. Studies showed that there is no tight correspondence 
between the clinical symptoms and the underlying pathology (Jack et al. 2011). Instead, as we 
saw in the former paragraph, a strong variability is observable: distributed plaques and a large 
number of tangles were reported in a subset of nondemented elders (Davis et al. 1999; Knopman 
et al. 2003; Price and Morris 1999) as well as cases of AD in the absence of a marked 
histopathology were described (Crystal et al. 1993; Riley, Snowdon, Markesbery 2002). 
At the same time, it is recognized that a trend exists for strong cellular and tissutal alterations 
to be already present at the moment when the first symptoms are expressed (Golde, Schneider, 
Koo 2011). Interestingly, formation of, respectively, neurofibrillary tangles and amyloid plaques, 
seem to be independent events with the former appearing earlier and in the limbic structures, 
preferentially, and the latter appearing in the neocortex (Braak and Braak 1997; Price et al. 1991; 
Price and Morris 1999). 
Moreover, there is now consensus that intra and extracellular deposits begin to accumulate 
long before the clinical disease becomes measurable. In particular, it was estimated that amyloid 
plaques accumulation may progress for some 10 to 20 years ahead of the clinical symptoms 
emergence (Benzinger et al. 2013; Villemagne et al. 2013). 
These observations have two intertwined effects on the current view of the disease. First, AD 
has a long asymptomatic phase during which the brain is pathophysiologically affected, no 
matter the unaltered cognitive performance of the subject. Second, the cognitive symptoms are 
an ultimate result of the long going pathophysiological processes due to the disease and likely 
represent a late time point for a disease-modifying intervention. Hence, much emphasis should 
be devoted to the research targeting the changes and the mechanisms underlying the early 
stages of the pathology. 
Indeed, the new criteria and guidelines for AD diagnosis, defined in 2011 (Jack et al. 2011), 
identify three stages of the disease: preclinical AD, MCI due to AD and dementia due to AD. Most 
notably, it is stressed the importance of counteracting the disease during its early phase. 
Moreover, while the diagnosis of MCI due to AD and AD dementia are mainly based on clinical 
assessment (American Psychiatric Association 2013), preclinical AD identification relies on 
biomarkers. Yet, the directions for preclinical AD diagnosis are presented as recommendations 
intended for research purposes. Their clinical employment is felt as premature and additional 
research on biomarkers is invoked. 
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3.3.7 Biomarkers 
Biomarkers are parameters that describe the status of a given biological process. Brought 
down to the pathology, a biomarker is an indicator of the existence and/or progression of the 
disease. 
A plethora of biomarkers has been developed in AD. They can be ascribed to different 
categories depending on the quality of the parameter – e.g. physiological, biochemical, anatomic 
– or the pathological stage that they are related to. 
From the genetic perspective, ApoE4 represents the strongest risk factor of developing AD 
(Saunders et al. 1993). However, as for amyloid plaques, ApoE4 does not provide information 
about the timing of clinical AD onset. 
The histopathological biomarkers consist of the historic hallmarks of AD: aggregates 
deposition and neuronal degeneration. Indeed, although the concentration of plaques is no 
longer considered a significant indicator of the severity of the clinical disease, amyloid plaques 
presence increases the risk of developing AD by about four folds (Chen et al. 2014). Notably, Aβ 
deposits may be non-invasively detected and quantified by means of a PET scanning method, 
where compounds able to bind to the plaques – e.g. Pittsburgh compound B (PiB), a radioactive 
analog of thioflavins – are employed as PET tracer (see Neural activity recording). Conversely, 
neurofibrillary tangles proved to fairly correlate with the cognitive symptoms (Giannakopoulos 
et al. 2003). Further, neuronal degradation, assessed as hippocampal volume reduction (Gosche 
et al. 2002) or atrophy on structural MRI in the temporal lobe and parietal cortices (Sperling and 
Johnson 2013b), was shown to highly correlate with both MCI and AD. Finally, better than 
neuronal injury and neurofibrillary tangles deposition, synaptic loss appears to be the strongest 
correlate of the clinical symptoms (Terry et al. 1991). 
Much work has been done in assessing biochemical biomarkers (Lista et al. 2014). These 
studies have focused on the cerebrospinal fluid (CSF) since it is in physical contact with the brain 
- conversely, blood is separated from the neural tissues by the blood-brain barrier (BBB) – and it 
is safe and relatively simple to access through a lumbar puncture. In particular, two biomarkers 
emerged from this approach. The first is the concentration of Aβ42. Indeed, a 50 % lower level of 
Aβ42 was consistently reported in AD patients’ CSF (Andreasen and Zetterberg 2008; Blennow 
2004), a phenomenon explained as complementary to Aβ aggregation in amyloid plaques 
(Strozyk et al. 2003). In addition, Aβ42/40 ratio was reported to decrease even more than Aβ42 
per se in AD patients, owing to a slight increase of Aβ40 level (Schoonenboom et al. 2005). 
Moreover, CSF Aβ42 has an accuracy of 65 – 75 % in predicting conversion from MCI to AD over 
2 years (Mitchell, Monge-Argiles, Sanchez-Paya 2010). Conversely, a second indicator of AD is 
the high level of CSF tau. Combined analysis of Aβ42 and tau levels in the CSF accounts for an 80 
– 95 % of sensitivity in discriminating AD (Forlenza, Diniz, Gattaz 2010; Hampel et al. 2004; 
Mattsson et al. 2009). 
However, it is important to note that CSF biomarkers alone, although compellingly accurate 
in discriminating AD and predicting MCI to AD conversion, are not sufficient to differentiate AD 
from other types of dementia (Lista et al. 2014). Likewise, it is worth noting that the predictive 
performance of Aβ42 and tau levels drops when tested on unselected populations (Mattsson and 
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Zetterberg 2009). Additionally, CSF gathering is an invasive procedure and, though rarely, it may 
cause post-lumbar puncture headache (PLPH) (Zetterberg et al. 2010). Consequently, patients 
are sometimes concerned about discomfort during the procedure. 
Finally, growing interest is now being attracted by the biomarkers of electrophysiological 
activity, including EEG and fMRI biomarkers. It is possible to extrapolate a wealth of parameters 
from the EEG signals by means of computer-aided tools ranging from time, frequency and time-
frequency features to non-linear dynamics. Several are altered in AD. For instance, a clear peak 
of alpha activity in waking subjects with eyes closed is often missing in AD patients (Pucci et al. 
1999). In addition, alpha and beta band slowing was reported (Dauwels, Vialatte, Cichocki 2010; 
Trambaiolli et al. 2011). Signal complexity is also reduced (Zhang et al. 2013). Likewise, 
coherence, as a measure of covariance between pairs of EEG signals, was consistently reported 
to be reduced in AD (Besthorn et al. 1997; Leuchter et al. 1987; Locatelli et al. 1998). 
Interestingly, the application of the machine-learning paradigm to exploit EEG coherence for AD 
diagnosis yielded encouraging results with sensitivity and specificity above 80 % (Trambaiolli et 
al. 2011). 
Functional imaging studies employing fMRI have consistently reported a diminished 
activation in the hippocampal region in response to mnemonic tasks in AD patients (Ewers et al. 
2011; Pihlajamaki, Jauhiainen, Soininen 2009). Interestingly, the opposite scenario is apparent 
in MCI patients. In this case, in fact, higher activation of the hippocampus in the course of the 
task has been generally described (Dickerson et al. 2005; Hämäläinen et al. 2007; Miller et al. 
2008) and, most strikingly, the degree of the activation correlated with the probability of 
 
Figure 5. Current model of AD biomarkers dynamics. This simple illustration describes the current most accredited model of 
biomarkers appearance in AD. Accordingly, Aβ load (red), first in the form diffusible oligomers and then as insoluble 
aggregates, is the first process to start. Subsequently, synaptic dysfunction (orange) and neuronal injury (green) begin. By 
the time when the first cognitive symptoms of dementia (purple) are detected, these biomarkers have already reached very 
high levels and even brain atrophy and shrinkage (blue) are observable. Image from (Sperling and Johnson 2013a). 
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progression to AD in a longitudinal study (Miller et al. 2008). These studies strongly indicate the 
existence of a phase of hippocampal hyperactivity that precedes the overt clinical AD and that 
disappears with the emergence of this latter. Yet, it is still debated whether the hippocampal 
hyperactivity could be compensatory or disease-aggravating (Bakker et al. 2012; Ewers et al. 
2011; Stargardt, Swaab, Bossers 2015). 
Some of the biomarkers that we reported here, including Aβ42 and tau CSF levels, were 
embodied, although only to a mere complementary purpose, in the revised criteria for AD 
diagnosis (American Psychiatric Association 2013; Jack et al. 2011). 
The integrated analysis of neuropsychological, CSF, and MRI features performed better than 
each single approach in predicting conversion from MCI to AD over 2 years (Cui et al. 2011). This 
result suggests that success in developing early, preclinical diagnosis of ongoing AD pathology 
will be achieved only through combining the analysis of many biomarkers. 
 
Figure 7. Model of the hypothetical progression of imaging biomarkers. The correlation between various imaging biomarkers 
and the different stages of the AD is illustrated in this scheme. Note, in particular, the slow increase of amyloid deposition 
(PIB-PET) that is believed to generally begin in the preclinical phase, long before the first symptoms, and the relatively rapid 
increase of task-driven brain activity (fMRI-task related brain activation) during the MCI phase followed by its decline after 
the onset of the overt AD phenotype. Image from (Ewers et al. 2011). 
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3.4 AD AND NETWORK DYSFUNCTIONS 
AD is linked to the alteration of many network features spanning several scales of network 
complexity. It is possible to separate them in two major categories: alterations of oscillatory 
activity and neural hyperactivity. 
3.4.1 Alterations of oscillations 
EEG-assessed theta power increases in the frontal regions with the shrinkage of hippocampal 
volume in MCI and AD (Grunwald et al. 2001). Moreover, theta power is markedly increased in 
MCI patients that subsequently progress to AD (Jelic et al. 2000). Beta power decrease is similarly 
predictive of AD (Jelic et al. 2000) while theta/alpha power ratio results altered in correlation 
with AD-linked cerebrovascular damage (Moretti et al. 2007). 
Whereas, alpha waves seem to disappear with the progression of the disease towards the 
most severe phases (Pucci et al. 1999; Smith 2005), beta oscillations parameters result well-
suited for separating AD from MCI (Poil et al. 2013), in particular when considering the 
broadening of peak width and bandwidth in AD (Huang et al. 2000; Poil et al. 2013). 
Finally, an overall slowing of the EEG, intended as shift of the power spectral density function 
towards lower frequencies, has long been known (Bennys et al. 2001; Rossini et al. 2006). 
3.4.2 Neural Hyperactivity 
Although Aβ causes depression of excitatory synapse (Palop et al. 2007; Shankar et al. 2007), 
its overall effect at the network level is of enhanced excitability (Palop and Mucke 2009). In 
accordance with increased network excitability, AD is linked to epilepsy as supported by the 
increased incidence of seizures in AD and the presence of seizures in the pedigree of many FAD 
families (Amatniek et al. 2006; Palop, Chin, Mucke 2006). In addition, epileptiform EEG activity 
was identified in several AD mouse models, including hAPPJ20 (Palop, Chin, Mucke 2006; Palop 
et al. 2007), hAPPJ9/FYN (Palop and Mucke 2009), Tg2576 (Chin et al. 2008) and hAPP/PS1 (Chin 
et al. 2008; Tanila, Minkeviciene, Dobszay 2008), PDAPP (Busche et al. 2015) and APdE9 
(Minkeviciene et al. 2009). In this latter, network activity was further investigated in vitro and 
neuronal hyperexcitability was observed in cortical and hippocampal slices (Minkeviciene et al. 
2009). Furthermore, hyperactive and hyperexcitable neurons were found both in the presence 
that in the absence of amyloid plaques in the APP23xPS45 mouse line (Busche et al. 2008; Busche 
et al. 2012). Remarkably, chronic administration of an antiepileptic drug, levetiracetam, to 
hAPPJ20 mice reduced neuronal hyperactivity and ameliorated the behavioral deficits as well as 
the synaptic plasticity impairment (Sanchez et al. 2012), whereas the reduction of Aβ levels by 
means of anti-Aβ immunotherapy worsened the phenotype of neuronal dysfunction by strongly 
increasing neuronal hyperactivity (Busche et al. 2015). 
Neural AD-linked hyperactivity, in particular at the hippocampal level, has been consistently 
reported in humans as well (Celone et al. 2006; Dickerson et al. 2005). Importantly, the 
hyperactivity is observable in the putative early stages of the disease, namely in MCI patients 
displaying light symptoms (see Biomarkers) (Celone et al. 2006; Dickerson et al. 2005; Putcha et 
al. 2011; Stargardt, Swaab, Bossers 2015). Further, it is worth noting that hyperactivity has been 
also observed in cognitively intact elderly characterized by Aβ deposition (Buckner et al. 2005; 
 
24 
Oh et al. 2015; Sperling et al. 2009) or familial risk (Bassett et al. 2006). Finally, treatment of MCI 
patients with levetiracetam reduced hippocampal hyperactivity and improved memory 
performance in amnestic MCI (Bakker et al. 2012). 
3.5 AD INVESTIGATION BY MEANS OF MOUSE MODELS 
In 1991, the discovery of the existence of a gene, APP, whose pathogenic mutation provides 
a fully penetrant form of AD (Goate et al. 1991), gave rise to the possibility to investigate the 
molecular actors involved in the etiology of FAD and, likely, in the mechanisms underlying the 
AD.  
Many mouse models have been and continue to be developed since then. Some are based 
on the knock-out of one or more of the genes responsible for the FAD, while many more are 
transgenic mice expressing FAD mutations. 
Knock-out models are useful to gather information concerning broad physiological aspects 
as well as pathological pathways in which the wt and the mutant proteins could be involved, 
respectively. For instance, APP knock-out mice present decreased locomotor activity, while PS1 
knock-out (PS1KO) mice die at the stage of embryos because of impaired somitogenesis and PS2 
knock-out (PS2KO) mice display pulmonary fibrosis and hemorrhage. Finally, conditional PSs 
knock-out in adult mice was shown to progressively induce the classical hallmarks of the disease, 
including neurodegeneration (Shen and Kelleher 2007). 
A large number of AD transgenic mouse models are in existence, each expressing a different 
combination of FAD mutations. However, none of the available model faithfully recapitulates all 
the aspects of AD pathogenesis. Conversely, each reproduces a specific assortment of AD 
features and is, thus, an incomplete model (Webster et al. 2014).The first AD mouse models that 
were developed, as well as the most used, are based on the expression of mutant human APP 
(hAPP). These animals appear to recapitulate the pre-dementia phase of the disease (Zahs and 
Ashe 2010). They generally exhibit amyloid plaques deposition as well as cognitive symptoms in 
an age-dependent fashion, with these latter occurring only in very old (18 – 24 months) mice 
(Duyckaerts, Potier, Delatour 2008). 
On the contrary, the majority of models expressing mutated forms of human PS (hPS) do not 
display neurologic deficits nor plaques deposition. This is explained by the fact that the murine 
Aβ is less aggregating compared to the human one. Where both mutated hAPP and hPS are 
coexpressed in a double transgenic mouse, the production of Aβ42 strongly increases and 
plaques deposition and cognitive symptoms are anticipated with the respect to the hAPP single 
transgenic mouse (Duyckaerts, Potier, Delatour 2008). 
The expression of a mutated form of hAPP neither alone nor in combination with a mutated 
hPS is sufficient to cause any significant tau pathology. Therefore, in order to investigate the 
neurofibrillary component of AD, transgenic lines expressing variants of human tau protein are 
employed (Zahs and Ashe 2010). However, tau mutations do not cause AD but fronto-temporal 
dementia. In some of these lines brain atrophy is observed and only in such cases cognitive 
deficits emerge as well. Moreover, Aβ has been proved to potentiate the neurofibrillary 
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pathology in these lines, consistently with the hypothesis positing tau-related anomalies to be 
downstream to Aβ (Hardy and Selkoe 2002). 
Altogether, mouse models represent a valuable tool for the research on AD. Notably, mice 
and humans have a high level of phylogenetic conservation in the architecture as well as in the 
circuitry and function of the hippocampus. Nevertheless, considering the failures of the clinical 
trial after the success of the therapies in murine setting, it is important to recognize that AD 
mouse models do not entirely recapitulate the AD phenotype. Firstly, since they are based on 
FAD mutations, they rather represent a model of the dominant autosomal forms of the disease. 
Secondly, considering the general lack of tau pathology and neurodegeneration, intended as 
neuronal loss, AD mouse model might, most commonly, reproduce preclinical stages of the 
disease (Zahs and Ashe 2010). 
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4 THE EXPERIMENTAL APPROACH 
In view of the vast assortment of AD mouse models along with the corollary of specific 
features of their AD-like phenotype, a short introduction is required in order to present the 
characteristics of the AD models chosen for this study. In addition, the overview on our 
experimental setting is extended to include a review of the effects of urethane anesthesia on 
brain electrophysiological activity. 
4.1 AD MOUSE MODELS BASED ON MUTANT PS2 
Two FAD mouse models were employed in this study: the single transgenic line PS2.30H 
(Richards et al. 2003) which is homozygous for the human PS2-N141I mutation (Borchelt et al. 
1996) and the double homozygous transgenic line B6.152H that presents the human PSEN2 
N141I (Volga/German) mutation in combination with the human APP KM670/671NL (Swedish) 
mutation (Ozmen et al. 2009). In these lines, the human PS2-N141I is under the control of the 
mouse prion protein promoter, while the human APP Swedish mutation is under the control of 
the Thy-1 promoter. Both transgenes are in homozygosity. 
Although it is also active in thymocytes, lymphoid tissue and even some glial cells, the Thy-1 
(also known as Thy-1.2) promoter has been modified (Caroni 1997; Vidal et al. 1990) to obtain a 
brain-specific neuronal promoter. The mouse prion promoter was suggested to be specific for 
neuronal cells (Maskri et al. 2004), however the cellular prion-protein is significantly expressed 
also in astrocytes (Lima et al. 2007; Moser et al. 1995), and, in astrocytes from PS2.30H mice, 
the over-expression of PS2 was also confirmed by Western blotting (unpublished data). For what 
concerns the pathological features, B6.152H mice present no plaques at 3 months, overt amyloid 
deposition at 6 months and heavy plaque deposition at 10 months of age (Ozmen et al. 2009). 
On the other hand, plaques deposition has never been assessed in PS2.30H mice. Further, 
B6.152H and PS2.30H lines present different Aβ load levels and Aβ42/Aβ40 ratios as early as 2-
weeks of age (Kipanyula et al. 2012). Finally, due to PS2-N141 expression, both AD mouse models 
are characterized by similar precocious Ca2+ dysregulation, as it was demonstrated in neonatal 
primary neuronal cultures at 10-12 days in vitro as well as in acute brain slice preparations from 
2-week-old mice (Kipanyula et al. 2012). In B6.152H mice, while cognitive impairment was 
detected by the Morris water maze only at 8 and 12 months of age, on the other hand an 
increase in LTP and post-tetanic potentiation in the DG has been reported as early as 3 months 
(Poirier et al. 2010). No reported study has characterized the PS2.30H line in terms of behavior 
yet. However, another model, expressing the PS2-N141I mutation under the control of the 
neuron-specific enolase (NSE) promoter, was proved to be cognitively impaired and to exhibit 
enhanced anxiety at 12- 18-months of age (Yuk et al. 2009). 
Altogether, the PS2.30H and B6.152H lines are particularly suited to address the early effects 
of Ca2+ homeostasis alteration and Aβ load at the network level. 
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4.2 URETHANE ANESTHESIA 
Urethane is an anesthetic that has long been used in neurophysiological research, in particular 
for investigating hippocampal oscillatory activities (Kramis, Vanderwolf, Bland 1975; 
Vandecasteele et al. 2014). Yet, its mechanisms of action are poorly understood. In vitro 
experiments on frog cells expressing recombinant neurotransmitter receptors, suggested that 
urethane exerts its action by weakly affecting multiple targets: it reduced the NMDA and the 
AMPA receptor-mediated excitatory currents by 10 % and 18 %, respectively, and enhanced 
GABA-A receptor-mediated inhibitory current by 23 % (Hara and Harris 2002). However, another 
in vitro study found no effect of urethane on PSPs, either excitatory or inhibitory in rat visual 
cortex acute slices. On the other hand, it reported a depression of pyramidal neurons firing rate 
due to shunting inhibition, operated by Ba2+-sensitive K+ leak currents (Sceniak and MacIver 
2006). 
Theta oscillations are a prominent hippocampal feature under urethane anesthesia (Buzsáki 
2002). Nevertheless, hippocampal theta in the anesthetized animal has historically been 
distinguished from the awake animal theta on the basis of the pharmacological sensitivity to the 
muscarinic blocker atropine. While atropine exerts no substantial effect on theta oscillations in 
the awake behaving animal (Buzsáki et al. 1986), conversely it abrogates theta rhythm under 
urethane anesthesia (Kramis, Vanderwolf, Bland 1975). 
Notably, urethane induces spontaneous sleep-like alternations of slow oscillations (SO) (0.2-
1.2 Hz) and theta (3-4 Hz) dominated brain states (Pagliardini, Gosgnach, Dickson 2013). The 
name “slow oscillations” was preferred over “delta” (Wolansky et al. 2006) because of the 
similarity with the previously described cortical SO (Steriade, Nunez, Amzica 1993). Theta-
dominated states are also accompanied by gamma (25-40 Hz) power increase. These 
alternations are reminiscent, respectively, of the rapid-eye movement (REM) and the slow-wave 
sleep (SWS) phases of the natural sleep cycle. Interestingly, the respiratory activity and the body 
temperature alternate in a similar fashion, further supporting the notion of urethane 
determining a sleep-like physiological state. 
Recently, two hippocampal theta activities were reported to simultaneously exist in the mouse 
hippocampus under urethane anesthesia (Yanovsky et al. 2014). A generally faster one (3-6 Hz), 
called theta, that is sensitive to atropine and has the maximum power at the hippocampal 
fissure, and a slower one (2–5 Hz), that is atropine resistant and displays the maximum amplitude 
in the hilus of the DG. This latter rhythm was named “hippocampal respiration-induced rhythm” 
(HRR) by the authors, after two observations: (i) HRR has the same frequency of respiration and 
(ii) tracheotomy abrogates HRR. However, it is important to notice that both oscillations were 
investigated in response to noxious stimulation, which is known to trigger theta activity along 
with an increase of muscle tone, under urethane (Pagliardini, Gosgnach, Dickson 2013). 
Conversely, the spontaneous theta-dominated state is accompanied by muscle relaxation 
(Clement et al. 2008; Pagliardini, Gosgnach, Dickson 2013). 
It is interesting to consider a wide-range and, to our knowledge uninvestigated, effect that 
urethane anesthesia could have on the oscillatory pattern. Urethane anesthesia is known to 
induce a drastic decrease of the mean frequency of hippocampal theta activity to 2 - 6 Hz (Kiss 
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et al. 2013; Pagliardini, Gosgnach, Dickson 2013; Yanovsky et al. 2014) from 6-9 Hz in the 
behaving animal (Buzsáki et al. 2003). At the same time, the frequencies of brain rhythms were 
described to be linked one to the other by a ratio corresponding to ~ 2.72 (e, Nepler’s number) 
(Buzsáki, Logothetis, Singer 2013; Penttonen and Buzsáki 2003). Therefore, we reason that, 
along with theta, it is possible that all distinct oscillations were lowered after the effects of the 
anesthetic. 
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5 PURPOSE OF THE WORK 
After the failure of Aβ-targeting therapies in clinical trials, one possible explanation is the 
fact that the treated patients had already fully developed the disease, as revealed by combined 
fMRI and cognitive assessment (Golde, Schneider, Koo 2011). At that point it is possible that Aβ-
processing modifying drugs could exert very limited therapeutic effect, given that the associated 
neurodegeneration has already started. New clinical trials will require subjects at preclinical 
stages of AD, i.e. who show AD brain alterations and are likely to progress to MCI and AD during 
the trial period (Jagust 2016). 
These discouraging results also highlight the urgency of early biomarkers that reliably 
indicate the undercover developing disease and that predict the overt onset of the first clinical 
symptoms with years of advance. 
From this perspective, PET/CSF and brain volumetric biomarkers proved to be valuable tools 
for predicting MCI to AD conversion over 2 years. Yet, the moment when the brain has already 
started to shrink is anyhow likely to be very late, implying that a hypothetically effective disease-
modifying therapy would yield no appreciable improvement because of the other detrimental 
mechanisms that have, meanwhile, established. Likewise, the alterations of brain oscillations 
were assessed in subjects already presenting symptoms of cognitive decline. 
Conversely, the importance of AD mouse models lies in the possibility to address potential 
changes of oscillatory activity that precede the first symptoms. 
Dysregulation of cellular Ca2+ homeostasis, Ca2+ hyperactivity and hyper-excitability appear 
to be among the first alterations observable in different AD mouse models (Camandola and 
Mattson 2011; Kipanyula et al. 2012; Stargardt, Swaab, Bossers 2015; Zampese et al. 2011b). In 
particular early neuronal impairment of physiological Ca2+ homeostasis has been described in 
the AD mouse models based on PS2-N141I (Kipanyula et al. 2012). Given that all FAD-linked 
mutations in PS2 determine profound alteration of Ca2+ signaling in mouse neuronal cells as well 
as in fibroblasts obtained by FAD patients, well before the onset of the cognitive decline 
(Giacomello et al. 2005; Zatti et al. 2006), it can be argued that addressing PS2 dependent 
hyperexcitability, in the absence or presence of Aβ accumulation, might help defining early 
markers of disease progression. In particular, we asked whether and from which stage of the 
disease it is possible to detect the effects of these modifications at the network level in the AD 
mouse lines PS2.30H and B6.152H, expressing the PS2-N141I in the absence or presence of 
hAPPswe respectively (Kipanyula et al. 2012). 
For this purpose, we recorded in vivo the spontaneous LFP activity in the DG of mice under 
urethane anesthesia at different ages and investigated the oscillatory activity. To our knowledge, 
only few studies have addressed spontaneous hippocampal oscillatory activity in AD mouse 
models in vivo at early stages at the disease (Born et al. 2014; Ittner et al. 2014; Verret et al. 
2012). Importantly, this is the first study addressing these aspects in a mouse model that does 
not express hAPP. 
This work has been carried out in collaboration with Prof. S. Vassanelli (DBS) and Prof. G. 
Sparacino (DEI), of the University of Padua.  
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6 MATERIALS AND METHODS 
6.1 ANIMALS 
All experimental procedures were carried out in compliance with the Italian animal welfare 
regulations. The utmost care was taken to minimize animal suffering. Due to the system-level 
approach of this work, the in vivo techniques were a necessary choice. The electrophysiological 
recordings were obtained from 11, 8, 8 (3-month-old), 10, 12, 12 (6-month-old) and 7, 4, 5 (12-
month-old) wt, PS2.30H and B6.152H mice respectively with a tolerance of 1 week for the 3-6 
month groups and 2 weeks for the 12 month group; IHC and ELISA experiments were carried out 
with 3-4 animals per group. Females were chosen for all the experiments because in the human 
pathology women are most affected (Alzheimer's Association, 2015; Schmidt et al. 2008), and 
B6.152H follow this trend (Ozmen et al. 2009). 
6.2 ACUTE ANIMAL PREPARATION 
Mice were anesthetized by intraperitoneal injection of urethane (1.5-2 mg/g, U2500 - Sigma-
Aldrich) dissolved in 0.9% NaCl physiological saline. In particular, the anesthetic effect was very 
variable and sensitive to small differences in dosage; hence, an initial dose of 1.2 mg/g was 
injected and additional doses (0.15 mg/g) were administered as necessary (Namgung, Valcourt, 
Routtenberg 1995). Absence of reaction to noxious stimuli (e.g. hind paw pinches) ensured the 
surgical plane of anesthesia. Body temperature was kept at 37 ± 0.5 °C by means of a servo-
controlled heating pad (ATC1000 – World Precision Instruments, Inc.). Krebs solution (0.1 ml) 
was subcutaneously administered every two hours in order to maintain hydration levels. 
The head was restrained in a stereotaxic frame and the skull was exposed. A hole was drilled 
at the site for inserting the recording electrode in the dentate gyrus region of the DG which was 
located according to (Huang et al. 2012) – about 2.4 mm posterior to bregma, 1.2 mm lateral to 
midline. The left hemisphere was selected provided that amyloid plaques and neurofibrillary 
tangles deposition is stronger in this hemisphere (Khan et al. 2014). 
The cavity over the skull was filled with Krebs saline solution and a silver chloride reference 
electrode was dipped within. 
Glass electrodes for local field potential (LFP) recording (0.9-1.6 MΩ tip resistance) were 
obtained from borosilicate capillaries (GB150T-10 – Science Products GmbH) pulled with a P-97 
micropipette puller (Sutter Instrument Company) and were filled with Krebs saline solution. 
In each animal, the LFP signal was serially acquired at three different depths from the 
meninges: 1.7 mm, 1.8 mm and 1.9 mm. These depths correspond to the molecular layer, the 
granule cell layer and the polymorphic layer of the DG. 
Heart beat was monitored through electrocardiogram (ECG) recording. ECG positive and 
negative derivations were subcutaneously inserted in the forelimbs. A high accuracy 
temperature probe was leaned against chest wall, on the side of the body, to monitor respiration 
(IT-23, World Precision Instruments). 
 
31 
At the end of the electrophysiological experiment, mice were euthanized by excess of anesthesia 
and the brain was dissected. The left hemisphere was intended for histological investigations 
and was fixed in 4 % paraformaldehyde (PFA 4% in Tris-buffer saline, TBS: 150 mM NaCl, 50 mM 
Tris, pH adjusted to 7.4 with HCl). Conversely, the right-hemisphere cortex and hippocampus 
were snap-frozen in liquid nitrogen for molecular assays. 
6.3 ELECTROPHYSIOLOGY 
6.3.1 Data acquisition 
The LFP signal was 10X amplified using an Axoclamp-2B amplifier with an HS-2Ax1LU 
headstage (Axon Instruments Inc.) in bridged mode. A custom-made amplifier provided further 
10X amplification along with 4-pole butterworth low-pass filtering at 1 kHz. The ECG signal was 
10X amplified and band-passed between 1 and 100 Hz by means of a DAM50 amplifier (World 
Precision Instruments). Respiration-induced movements of the chest wall were converted in 
voltage fluctuation by exploiting the piezoelectric properties of the temperature probe. 
Respiration signal was 100X amplified and band-passed between 0.1 and 100 Hz by means of a 
DP-301 amplifier (Warner Instruments). 
All signal were digitalized at 10 kHz by means of a PCI-6071E I/O card (-0.5 – 0.5 V input range) 
combined with a BNC-2090 terminal block (National Instruments) in differential mode and 
recorded through a custom-made LabView (National Instruments) script. Each recording lasted 
from 15 minutes to two hours. 
6.3.2 Signal processing 
Analysis of the signals was performed offline in MATLAB (Mathworks). Custom-written and 
built-in scripts were employed. 
Filtering was achieved through a zero-phase distortion filtering function (filtfilt.m) which 
processed the data in both the forward and reverse direction. Butterworth transfer function 
coefficients were employed (butter.m). 
All signals were high-pass filtered at 0.05 Hz (3rd order filter). Next, LFP, ECG and respiration 
signals were low-pass filtered (5th order filter), respectively, at 250 Hz, 25 Hz and 10 Hz. Finally, 
they were down-sampled (downsample.m) to 500 Hz, 50 Hz and 20 Hz, respectively. LFP signals 
were further low-pass filtered at 10 Hz and down-sampled to 20 Hz for spectrograms 
computation in the SO and theta oscillations ranges. 
6.3.3 Time-frequency analysis 
In order to inspect the temporal fluctuations of frequency content in the recordings, LFP, ECG 
and respiration signals were time-frequency decomposed in the 0.1 - 10 Hz, 7 – 13 Hz and 1 – 5 
Hz range, respectively, and the relative spectrograms were obtained. This was achieved 
employing a custom-written routine, based on a MATLAB built-in function (cwtft.m), that uses a 
fast Fourier transform algorithm to compute the Morlet continuous wavelet transform. 
From each recording, as a result of the time frequency inspection, one 5-min window was 
selected and included for further analysis, provided that LFP theta activity, heart beat rate (HBR) 
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and respiration rate (RR) were stable throughout the entire window. Recordings that did not 
present time-windows fulfilling the inclusion criteria were discarded. 
6.3.4 Spectral analysis 
LFP power spectral density (PSD) was calculated for each 5-min window through the Welch 
estimate method (pwelch.m). The method divides the signal in overlapping sections, windows 
them with a Hamming windows and computes the periodogram for each window. Finally, the 
periodograms are averaged into the PSD estimate. Hamming windows of 2 sec were used with 
an overlap of 50 %. 
The spectral power in the different wave band was obtained by computing the integral with the 
trapezoidal method (trapz.m) under the PSD curve in the relative frequency range. 
6.3.5 Spectral steepness 
PSD function steepness was evaluated as the slope coefficient of the PSD linear fitting. For 
each 5-min window the PSD function was interpolated (polyfit.m) with a least-squares line in the 
range 10 – 100 Hz. 
6.3.6 PAC analysis 
For theta-higher frequency PAC index analysis, each 5-min window was, first, bandpass filtered 
in the theta band (3rd order filter) and in the specific higher frequency band band (6th order filter) 
as described above. Next, the Hilbert transform (hilbert.m) was applied to each time-series 
obtained from filtering. Then, phase angle and amplitude time-series were extracted from the 
Hilbert transform of theta and the higher frequency filtering, respectively. Finally, theta-higher 
frequency PAC index was computed by means of the general linear model (GLM) as described 
(Penny et al. 2008). Basically, the amplitude of the faster oscillation is modeled by multiple 
regression and the index is the proportion of variance explained by the model. 
6.3.7 Statistical analysis 
Power spectra, band power, PSD slope and PAC indices obtained from the recordings at the 
three depths were averaged within animals to obtain grand mean quantifications for each 
animal. Those experiments where it was not possible to obtain one 5-min window from each 
depth, were discarded from the analysis. 
Differences among means were tested by performing Kruskal-Wallis nonparametric test. 
Where Kruskal-Wallis test resulted in the existence of a pair of different populations, differences 
between means where tested with Mann-Whitney Rank Sum test. 
The Mann-Whitney Rank Sum test was performed as an unpaired two-tailed test. 
Statistical tests were carried out in GraphPad Prism. All data are expressed as mean ± SEM. 
The α level of significance was 0.05. 
6.4 HISTOLOGY 
To mark the position of the LFP electrode insertion (see Figure 6), at the end of the experiment 
the electrode was withdrawn, dipped in 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine 
perchlorate (DiI) (0.05 % in DMSO) and then carefully reinserted to the same stereotaxic 
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coordinates of the mid depth. Next, the brain was dissected and the left hemisphere was fixed 
in 4 % PFA for 48 hours. After 3 times washing with TBS, the hemibrain was cut parallel to the 
sagittal plane with a vibratome (Leica VT1000 S), yielding 50 µm-thick slices. Finally, slices were 
either stained with toluidine blue and mounted by means of Mowiol mounting medium, or 
conserved for immunohistochemistry (IHC), see below. The electrode insertion site was 
visualized by epifluorescence microscopy using a ViCo microscope with a 4x objective (Nikon). 
6.5 IMMUNOHISTOCHEMISTRY 
6.5.1 Staining and acquisition 
Mid-sagittal brain slices were cut from the left hemisphere as described above and conserved 
in TBS at 4 °C until employed (up to two weeks, maximum) for dorsal hippocampus 
immunostaining. For staining, slices were selected over a range of 400 µm, excluding the 
insertion site. Consistency of the selected anatomical position was ensured by ocular 
identification of several anatomical features in the first and last slice of the range, including the 
shape of the hippocampal section, the size of the left ventricle and caudoputamen and the 
thickness of the mid-brain region. 
Immunostaining was performed on floating slices. Fist, slices were washed in TBS and 
incubated in 70% formic acid for 5 minutes to allow Aβ-antigen retrieval. Then, slices were 
incubated in permeabilizing/blocking buffer containing 0.2% TritonX-100 and 5% goat serum in 
TBS for 1 hour at room temperature (RT). Next, they were incubated overnight at 4 °C in the 
primary antibody (Ab1) solution, which consisted of the blocking buffer plus the Ab1s mouse 
anti-Aβ 17-24 (4G8, Covance, 1:1000) and rabbit anti-GFAP (Dako, 1:400). Then, slices were 
incubated in the secondary antibody (Ab2) solution, which consisted of the blocking buffer plus 
the Ab2s Alexa488-conjugated donkey anti-rabbit (Invitrogen, 1:1000) and Alexa555 conjugated 
goat anti-mouse (Invitrogen, 1:1000). Incubation in the Ab2 solution lasted 1 h at RT in the dark. 
Finally, slices were mounted on microscope slides by means of a Mowiol mounting medium and 
stored at 4°C until visualized via confocal microscopy. Every step described was separated from 
one other by 3 washes in TBS (5 min each). 
Samples were imaged by means of the confocal laser microscope Leica SP5 with a 20X air 
objective. During acquisition, parameters for laser intensity and photomultiplier gain were kept 
constant. 
6.5.2 Analysis 
For astrogliosis quantification, we considered the average brightness level of GFAP labelling in 
the HF region. In each image, a region of interest (ROI) was traced encompassing the following 
regions: subiculum, DG, CA3 and CA1 (see Figure 11); for the cortex, a rectangular ROI of 
invariant size was drawn. Then, the average 8-bit pixel intensity (0-255) was computed for each 
ROI. Image analysis was performed in Fiji. Three slice for each mice were used to quantify the 
mean average value of the selected regions. The three lines were processed in parallel. 
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Statistical comparison of mean brightness intensities was carried out in GraphPad Prism. The 
unpaired two-tailed Mann-Whitney Rank Sum test was employed. All data are expressed as 
mean ± SEM. The α level of significance was 0.05. 
6.6 ELISA 
After brain extraction from the skull, the right hemisphere was dissected while kept in ice-cold 
HBSS (Ca2+ and Mg2+ free). The hippocampus and the cortex were isolated and placed in 
cryovials. These latter were snap-frozen in liquid nitrogen and stored at -80°C until employed for 
ELISA. 
Total Aβ was extracted according to the following procedure designed to separate two 
fractions, the first one that was extracted by a RIPA solution containing SDS at high concentration 
(2%) and the second one that was extracted by a strong acidic solution. Briefly, the frozen tissue 
was thawed, weighted and diluted 1:5 weight/volume (w/v) in in RIPA buffer (50 mM Tris, 150 
mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 2% SDS) also containing protease and 
phosphatase inhibitors (cOmplete, Mini, protease inhibitor cocktail, Roche; PhosSTOP, 
phosphatase inhibitor cocktail, Roche). Next, the tissue was cold homogenized by mechanical 
trituration through an insulin syringe. Then, the total volume was centrifuged (Beckman TLA-
120.1 Rmax 3.89 cm – Tube, 343776 – 0.5 ml) at 50,000 rpm (109,000 g) for 1 h at 4°C. The 
supernatant was gathered, split in two aliquots constituting the “RIPA fraction” and stocked at  
-80°C until employed. 
The remaining pellet was diluted 1/5 w/v in a solution of 70% formic acid (FA) in deionized 
water and resuspended through a micropipette. The FA fraction was left on ice for 30 min and, 
then, sonicated for 5 min at 4°C (485 W). It was subsequently centrifuged at 50,000 rpm for 1 h 
at 4°C, as above. The supernatant was split in aliquots constituting the “FA fraction” and stored 
at -80°C until employed. 
At the moment of performing the ELISA assay, the RIPA fraction was diluted at least 1:10 in 
the assay standard diluent while an aliquot of the FA fraction was centrifuged and diluted 1:10 
in a neutralization buffer (1 M Tris, 0.1 M NaCl, , pH adjusted to 7) also containing 0.025% phenol 
red to check for pH adjustment. The neutralized FA extract was assayed directly or upon further 
dilution according to the expected A load. 
The Wako assay 290-62601 was employed for the quantification of Aβ42. This assay detects both 
the human and murine Aβ and is, hence, suited for the wt and the PS2.30H line, where only 
murine Aβ is produced, as well as for the B6.152H line, where human and murine Aβ are co-
expressed. 
6.6.1 Statistical analysis 
Differences among average quantities of Aβ40 and Aβ42 were tested by performing Student’s 
t-test, as an unpaired two-tailed test. Welch’s correction was applied. 
Statistical tests were carried out in GraphPad Prism. All data are expressed as mean ± SEM. 
The α level of significance was 0.05.  
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7 RESULTS 
The consequences of FAD-PS2 mutations on Ca2+ homeostasis have been investigated in 
different model cells in vitro (Zampese et al. 2011a; Zampese et al. 2011b; Zatti et al. 2006) and 
specifically in situ for the AD mouse models based on the mutant PS2-N141I, expressed either 
alone or in combination with the APPswe mutation, respectively  in the PS2.30H single transgenic 
and in the B6.152H double transgenic mouse lines (Kipanyula et al. 2012; Ozmen et al. 2009). 
Compelling evidence has been provided for dysregulation of neuronal Ca2+ homeostasis and Ca2+ 
hyperactivity in hippocampal slices as early as two weeks after birth, being effects that markedly 
precede the appearance of the classical hallmarks of AD, namely the surge of amyloid 
accumulation and deposition in brain tissues (Kipanyula et al. 2012; Ozmen et al. 2009). 
Here, we addressed the network level outcomes of the PS2-N141I in the same mouse lines. In 
particular, we focused on the spontaneous oscillatory LFP activity of the DG, a brain region that 
is strongly and early affected by the disease in humans. We performed in vivo extracellular 
recordings in mice under urethane anesthesia while targeting 3 sites in the dorsal hippocampus, 
corresponding to the molecular, granule cell and polymorphic layers (ml, gc, pl) of the DG. Since 
the B6.152H line presents amyloid plaques deposition starting at 6 months of age (Ozmen et al. 
2009), it seemed convenient to select this latter age as a reference time point. In addition, we 
investigated an early and a late time point, 3 and 12 months of age, respectively. The 
electrophysiological approach was corroborated by IHC and ELISA experiments in order to 
provide a molecular-histological framework to the brain activity observations. 
 
Figure 9. LFP recording sites. The LFP signal was recorded by means of an Ag/AgCl electrode inserted in the DG of the left-
hemisphere dorsal hippocampus. In each experiment, the electrode was sequentially targeted to the three DG layer, as 
reported in the diagram on the right. The top-left image is a sagittal proximo-medial hippocampal slice illustrating the 
electrode insertion position, labelled at the end of the experiment by DiI and assessed through HC. The stereotaxic positions 
of targeted recording sites are also indicated. The bottom-left image is a whole brain sagittal slice from the Allen Mouse 
Brain volumetric Atlas 2012. The region of the HF is highlighted. 
 
 
 
 
 
 
36 
7.1 DEFINITION OF THE FREQUENCY BANDS 
The LFP signal that we recorded presented two prominent rhythms, a slower oscillation, 
generally peaking at less than 1 Hz and a faster one at about 2.5 – 3 Hz (see Figure 7). These 
bands closely correspond, respectively, to the slow oscillations (~ 0.2 – 1.2 Hz) and the theta 
waves (~ 2 – 6 Hz) previously described in the hippocampus by other studies where mice under 
urethane anesthesia were employed (Pagliardini, Gosgnach, Dickson 2013; Yanovsky et al. 2014). 
Therefore, we defined slow oscillations the rhythm in the range of 0.1 – 1.4 Hz and theta the 
oscillations in the range 1.7 – 4.7 Hz. The particularly low inferior limit accounts for the many 
cases where theta activity had a near 2 Hz frequency or slightly lower. 
Gamma band is classically confined approximately in the 30 – 90 Hz range (Buzsaki 2006a). 
However, this broad band has been recently shown to be further distinguishable in sub-bands, 
each accounting for a distinct mechanism of generation, on the basis of the degree to which the 
wave amplitude at each frequency is modulated as a function of a slower rhythm phase 
(Belluscio et al. 2012; Tort et al. 2010). Despite the lacking of a widely accepted convention over 
hippocampal gamma bands and nomenclature (Buzsáki and Wang 2012; Colgin and Moser 
2010), at least two gamma ranges are generally acknowledged in the < 100 Hz spectrum.  
Accordingly, we defined a SG band as 25 – 40 Hz (Pagliardini, Gosgnach, Dickson 2013), a HG 
band as 40 – 90 Hz and an epsilon band as 110 -190 Hz (Belluscio et al. 2012; Buzsáki and Wang 
2012; Freeman 2007; Scheffer-Teixeira et al. 2013). Finally, the beta band was defined between 
10 and 25 Hz (Lowry and Kay 2007). 
 
Figure 11. Frequency components of ECG, respiration and hippocampal LFP signals. A, Time-frequency spectrograms computed, 
respectively, from the ECG, respiration and hippocampal LFP traces simultaneously recorded in a 6–month-old wt mouse. Dashed 
lines indicate time window of the traces in B. B, LFP signal, from the time interval highlighted in A. The traces represent the same 
recording, yet broad-band, slow oscillation band and theta band filtered, respectively. C, Power spectrum computed from the same 
full-length LFP recording as in A. Slow oscillations and theta rhythm are prominent in the LFP signal. Theta oscillations and 
respiratory rhythm have the same frequency (2 – 3 Hz) and follow similar fluctuations of peak frequency and power. Slow oscillation 
power alternates coherently with that of theta. 
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7.2 HIPPOCAMPAL SLOW OSCILLATIONS, THETA AND RESPIRATION RHYTMS 
Urethane anesthesia slowed mice respiration rhythm to 2 – 4 Hz (see Figure 7), consistently 
with other studies (Depuy et al. 2011; Yanovsky et al. 2014). Moreover, respiratory rhythm was 
entrained in a regular fluctuation, as described by Dickson’s group (Pagliardini, Gosgnach, 
Dickson 2013).  
Spontaneous theta oscillations in the LFP recordings reliably had the same frequency of 
respiration and followed its fluctuation, similarly to the recently described hippocampal 
oscillation induced by respiration – HRR (Yanovsky et al. 2014).  
7.3 ALTERATION OF THE POWER SPECTRA DENSITY 
We first asked whether the oscillatory pattern of the three lines was comparable across the 
three aging stages that we considered (3, 6 and 12 months). When the mean power spectra 
were computed for each group and plotted as the logarithm of the power density against the 
logarithm of the frequency (i.e. “log-log” plot) (see Figure 8, left panels), a tendency to an age-
dependent overall decrease of the offset was observed in all genotypes. This phenomenon is 
better appreciable when power spectra are represented in the semi-log space (insets of Figure 
8). 
Next, in order to highlight alterations in the oscillatory activity of the three lines, we compared 
the mean power spectra of the animals by genotype at the different ages (see Figure 8, right 
panels). 
Interestingly, the PSD decay function of B6.152H mice, represented in log-log, appears to be 
rotated at across the theta peak, when compared with that of wt mice. In fact, the slow 
oscillations are left-shifted towards lower frequencies and the SG activity is increased in power, 
the effect being stronger at 3 and 6 months on age. 
We further investigated whether a broad-band alteration of the PSD function could underlay 
this observation. In particular, the slope coefficient has been described to be affected in several 
neurological diseases and disturbs, including Parkinson’s disease and schizophrenia (Voytek and 
Knight 2015). Therefore, we evaluated the steepness of the power spectra by linear fitting the 
PSD curve, represented in semi-log, in the 10 – 100 Hz range (see Figure 9). We found that the 
PSD decay is significantly steeper (p < 0.05, Mann-Whitney rank-sum test) in both 3- (B6.152H, -
0.257 ± 0.025; wt, -0.207 ± 0.020) and 6-month-old (B6.152H, -0.238 ± 0.024; wt, -0.199 ± 0.028) 
B6.152H mice compared to wt mice, although a tendency in the same direction is also noticeable 
at 12 months of age. Conversely, PSD steepness in PS2.30H mice was comparable (p ≥ 0.05, 
Mann-Whitney rank-sum test) with wt mice at each considered age. 
Figure 13. Power spectral density compared by age and genotype. Left panels report the average PSD of each age-genotype 
group, compared within genotypes. A general trend to a decrease of spectrum offset is observable across genotypes. Right 
panels report the same power spectra as in the left panels but compared within different ages. A trend to a shift of SO 
power towards lower frequencies is appreciable at all ages. A “shoulder” of broad-band increased power is notable in the 
B6.152H line at 3 months of age as well as in both the PS2.30H and B6.152H line at 6 months of age roughly in the 10 – 45 
Hz range. Spectra are represented in the “log-log” space. Inset-graphs in left panels are in semi-log representation, with 
the horizontal axis linearly scaled. Dotted lines represent ± SEM 
 
Figure 14. Power spectral den ity compared by age and genotype. Left panels report the average PSD of each age-genotype 
group, compared within genotypes. A general trend to a decrease of spectrum offset is observable across genotypes. Right 
panels report the same power spectra as in the left panels but compared within different ages. A trend to a shift of SO 
power towards lower frequencies is appreciable at all ages. A “shoulder” of broad-band increased power is notable in the 
B6.152H line at 3 months of age as well as in both the PS2.30H and B6.152H line at 6 months of age roughly in the 10 – 45 
Hz range. Spectra are represented in the “log-log” space. Inset-graphs in left panels are in semi-log representation, with 
the horizontal axis linearly scaled. Dotted lines represent ± SEM 
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Taken together, these results indicate an overall alteration of DG network dynamics under 
urethane anesthesia, as inferable through the analysis of the PSD slope coefficient, in B6.152H, 
but not PS2.30H mice, as soon as 3 months of age. 
7.4 ENHANCEMENT OF BETA AND GAMMA POWER 
Since the power spectrum appeared rotated in the lower frequencies (< 30 Hz), at least in the 
B6.152H line, we asked whether this could affect the power in the individual bands. Therefore, 
we obtained the power by computing the integral of the PSD function in each band (see Figure 
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Figure 15. PDS linear fit. A-C, Mean power spectra of each age-genotype group as presented in the right panels of Figure 8 
but limited to the ≤ 100 Hz frequencies and plotted in the semi-log space. Straight lines represent linear fitting computed in 
the range 10 – 100 Hz. SEM is not displayed for the sake of readability. D, Bar graph reporting the mean linear-fit slope 
coefficient for each age-genotype group. B6.152H mice present a significantly steeper decay at both 3 and 6 months of age 
with respect to the other mouse lines. The steepness appears to decrease with aging in B6.152H mice. Error bars represent 
± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Mann-Whitney rank-sum test. 
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 10, panels A – F) and we observed that all genotypes were statistically comparable (p ≥ 0.05, 
Mann-Whitney rank-sum test), at all ages, in terms of SO and theta power as well as concerning 
the power in the very high frequency epsilon band. On the other hand, alterations of the beta 
and/or gamma band power emerged in both lines at the age of 6 months. In particular, B6.152H 
mice presented both beta (B6.152H, 2.592e-3 ± 0.305e-3 mV2; wt, 1.177e-3 ± 0.317e-3 mV2) 
and SG (B6.152H, 1.347e-3 ± 0.179e-3 mV2; wt, 0.575e-3 ± 0.169e-3 mV2) power increase (p < 
0.05, Mann-Whitney rank-sum test) at 6 months of age with respect to wt mice. Similarly, in the 
PS2.30H line SG (PS2.30H, 1.115e-3 ± 0.190e-3 mV2) and HG (PS2.30H, 1.075e-3 ± 0.181e-3 mV2; 
wt, 0.593e-3 ± 0.193e-3 mV2) power were significantly enhanced compared to wt mice. 
Additionally, beta power was enhanced in 3-month-old B6.152H mice with respect to age-
matched PS2.30H mice (B6.152H, 2.592e-3 ± 0.305e-3 mV2; PS2.30H, 1.993e-3 ± 0.344e-3 mV2). 
At 12 months of age, the last time point we considered, the amplitude of all oscillations was 
comparable across genotypes. 
In conclusion, both PS2.30H and B6.152H lines present enhancement of the power in 
individual, yet not fully overlapping, bands encompassing the beta-gamma range, at 6 months 
of age. This variation from the wt phenotype results fully reversed at 12 months of age. 
7.5 THETA-GAMMA PHASE AMPLITUDE COUPLING 
Finally, we asked whether the spectral alterations that we observed could be accompanied by 
changes at a higher level of oscillatory network behavior, namely the phenomenon of frequency 
nesting. In particular we addressed the CFC between the phase of the theta oscillation and 
amplitude of higher frequencies. We quantified the PAC in the theta-beta, -SG, -HG and -epsilon 
classes by computing the GLM index as described in Materials and Methods (see Figure 10, 
panels G - J). According to the recommendations developed by the work of Aru J. et al. (Aru et 
al. 2015) for CFC investigation, we ensured (i) that the lower, modulating, frequency band 
actually corresponded to an oscillatory activity (i.e., theta) and (ii) that the bandwidth of higher, 
modulated, frequency always was at least 2 times the frequency of the modulating band. 
Nevertheless, we wish to highlight that, owing to our experimental framework, which was 
intended for assessing spontaneous activity, we could not verify to what degree the CFC coupling 
that we observed was due to causal relationship between the theta and the higher frequency 
oscillations. Therefore, it is possible that the levels of CFC that we report here were determined, 
at least to a certain degree, by common drive onto the DG network (Aru et al. 2015). 
In B6.152H mice, the pattern of alteration of PAC level in the different classes closely 
resembles that of power (see Figure 10, panels A – F). In fact, theta-beta (B6.152H, 0.168 ± 0.023; 
wt, 0.103 ± 0.013) as well as theta-SG (B6.152H, 0.210 ± 0.028; wt, 0.133 ± 0.018) PAC resulted 
Figure 17. Power and PAC. A-F, Bar graphs of mean power within individual oscillation bands, computed as the integral of 
PSD in the relative range. In B6.152H mice, power is significantly increased in the beta band at 3 months of age as well as 
in the beta and SG bands at 6 months of age. In PS2.30H mice, power is significantly increased in the SG and HG bands at 6 
months of age. No power difference is present at 12 months of age among genotypes. G-J, Bar graphs of mean GLM index 
of PAC within individual classes. In the B6.152H line, PAC level is increased in the theta-beta and -SG classes at 6 months of 
age. Both B6.152H and PS2.30H lines present reduced theta-epsilon PAC at 12 months of age. In 3- and 6-month-old 
PS2.30H mice, in spite of no statistical difference with wt mice, PAC level is significantly lower than B6.152H mice in the 
theta-beta (3 and 6 months), theta-SG (6 months) and theta-HG classes (6 months). Error bars represent ± SEM. *, p < 0.05; 
**, p < 0.01; ***, p < 0.001. Mann-Whitney rank-sum test. 
 
Figure 18. Power and PAC. A-F, Bar graphs of mean power within individual oscillation bands, computed as the integral of 
PSD in the relative range. In B6.152H mice, power is significantly increased in the beta band at 3 months of age as well as 
in the beta and SG bands at 6 months of age. In PS2.30H mice, power is significantly increased in the SG and HG bands at 6 
months of age. No power difference is present at 12 months of age among genotypes. G-J, Bar graphs of mean GLM index 
of PAC withi  individual class s. In the B6.152H line, PAC level is increas d in the theta-beta and -SG classes at 6 months of 
age. Both B6.152H and PS2.30H lines present reduced theta-epsilon PAC at 12 months of age. In 3- and 6-month-old 
PS2.30H mice, in spite of no statistical difference with wt mice, PAC level is significantly lower than B6.152H mice in the 
theta-beta (3 and 6 months), theta-SG (6 months) and the a-HG cl ss s (6 month ). Error bars represent ± SEM. *, p < 0.05; 
**, p < 0.01; ***, p < 0.001. Mann-Whitney rank-sum test. 
 
42 
significantly enhanced (p < 0.05, 
Mann-Whitney rank-sum test) in this 
line compared to wt mice at 6 months 
of age. On the contrary PS2.30H mice 
did not present any difference (p ≥ 
0.05, Mann-Whitney rank-sum test) 
with respect to wt mice either at 3 or 6 
months of age. Despite the increase of 
SG and HG power in 6-month-old 
PS2.30H mice, the level of PAC in the 
classes concerning those bands results 
unaffected or even, perhaps, slightly 
reduced, as suggested by the 
statistically significant difference 
existing with age-matched B6.152H 
mice in both the theta-SG (B6.152H, 
0.210 ± 0.028; PS2.30H, 0.120 ± 0.013) 
and the theta-HG (B6.152H, 0.206 ± 
0.029; PS2.30H, 0.144 ± 0.014) classes, 
as well as in the theta-beta class both 
at 3 (B6.152H, 0.176 ± 0.024; PS2.30H, 
0.096 ± 0.009) and 6 (B6.152H, 0.168 ± 
0.023; PS2.30H, 0.086 ± 0.009) months of age. Finally, both transgenic lines reported a 
diminished theta-epsilon PAC at 12 months (B6.152H, 0.101 ± 0.014; PS2.30H, 0.097 ± 0.017; 
wt, 0.152 ± 0.012). 
Taken together, these results indicate that the PS2.30H and B6.152H lines express markedly 
different alterations of network activity in terms of theta-higher frequency coupling at 3 and 6 
months of age. In particular, at 6 months of age, the former displays significant overcoupling in 
two of the considered classes, as opposite to the latter that reports no difference in any class, 
compared to the wt line. Notwithstanding the differences existing between the transgenic lines 
in the first two ages of our study, PAC levels of PS2.30H and B6.152H mice converge to similar 
values at 12 months of age. 
7.6 AMYLOID PLAQUE DEPOSITION AND ASTROGLIOSIS 
Among the major histopathological hallmarks of AD are the extracellular deposition of amyloid 
plaques and the establishment of gliosis, i.e. the sustained inflammatory glial response to 
insulting conditions. 
To provide histological disease correlates of the electrophysiological observations we 
obtained from our models, we evaluated the deposition of amyloid plaques as well as the 
presence of astrogliosis by IHC, at 3 and 6 months of age (see Materials and Methods). 
 
Figure 19. Cortical and hippocampal ROIs for amyloid plaques and 
astrogliosis analysis. Brain sagittal proximo-medial slice from a 6 
month-old B6.152H mouse. The sub-regions of the HF and portion of 
cortex that we defined as ROIs for our IHC analysis are illustrated. 
Abbreviations: CA, Cornu Ammonis; so, stratum oriens; sp, piramidal 
layer; sr, stratum radiatum; DG, Dentate Gyrus; mo, molecular layer; 
sg, granule cell layer; pl, polymorphic layer. Aβ, red; GFAP, green. 
Brightness and contrast were adjusted for each colour channel for 
the sake of the illustration aim. 
 
 
Figure 20. Cortical and hippocampal ROIs for amyloid plaques and 
astrogliosis analysis. Brain sagittal proximo-medial slice from a 6 
month-old B6.152H mouse. The sub-regions of the HF and portion of 
cortex that we defined as ROIs for our IHC analysis are illustrated. 
Abbreviations: CA, Cornu Ammonis; so, stratum oriens; sp, piramidal 
layer; sr, stratum radiatum; DG, Dentate Gyrus; mo, molecular layer; 
sg, granule cell layer; pl, polymorphic layer. Aβ, red; GFAP, green. 
Brightness and contrast were adjusted for each colour channel for 
the sake of the illustration aim. 
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The antibody that we employed to target Aβ – 4G8 – has been raised against the 17-24 epitope 
of the peptide. This latter is a portion of the APP extracellular domain - that is not buried within 
the lipid bilayer - before the secretase-operated cleavage. The 4G8 antibody labels both Aβ 
peptides, present in aggregates and amyloid plaques, as well as full-length APP and its β-carboxy-
terminal fragment, at the membrane level.  
We consistently found marked plaques deposition in the HF, especially in the subiculum and, 
to a lesser degree, in the DG, as well as in the cerebral cortex of the 6-month-old B6.152H 
compared to wt mice (n = 3, each group) (see Figure 12). These findings confirm and expand 
previous observations obtained in B6.152H mice by the Congo red approach, which mainly 
detects the fibril status of the deposits (Ozmen et al. 2009). On the contrary, extracellular 
amyloid aggregates were not observed in 3 month-old B6.152H mice (n = 3). However, a 
noticeable intracellular staining was detected in all considered territories (see magnification in 
inset of Figure 12, panel C), yet it was particularly strong in the subiculum and in the pyramidal 
layer (sp, stratum pyramidalis) of the CA1 region. Interestingly, as soon as the sp enters the CA3 
sub-field, the intracellular labelling appears to drastically fade, in favor of a diffused staining of 
the CA3 stratum radiatum (sr) (see magnification in inset of Figure 12, panel C). Although we 
cannot affirm that the intracellular labelling that we observe represents Aβ accumulation, rather 
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Figure 23. GFAP staining intensity. The degree of astrocytes reactivity in the HF and its sub-regions, as well as in the cortex, was 
evaluated through the intensity of GFAP staining, which was performed, imaged and analyzed under standardized parameters. 
Astrocytes reactivity results significantly enhanced, with respect to wt, only in the B6.152H line at 6 months. For all groups, n = 3. 
Error bars represent ± SEM. *, p < 0.05. Mann-Whitney rank-sum test. 
 
 
 
Figure 21. Aβ load and astrogliosis. A-D, Representative images of slices from a 6-month-old wt mouse (A), a 6-month-old 
PS2.30H mouse (B), a 3-month-old B6.152H mouse (C) and a 6-month-old B6.152H mouse (D), where Aβ (left panels) and 
GFAP (right panels) were immunolabelled. Images in the same raw were acquired from the same slice. At 3 months of age, 
B6.152H mice display a strong intracellular accumulation of Aβ and/or Aβ-containing peptides, in particular in the subiculum 
and in the sp layer of CA1. The same layer in CA3 does not mirror the phenomenon. Conversely, in the CA3 subfield the sr 
layer appears diffusely labelled. Insets in C, magnification of a CA3 sp-sr and a subiculum detail, respectively. No deposition 
of amyloid plaques is observable in slices other than from the B6.152H line at 6 months of age (D). Plaques are mainly 
localized in the subiculum and, to a lesser extent, in the DG and in the cortex. Inset in D, magnification of a plaque-containing 
subiculum detail. GFAP labelling markedly increases in 6-month-old B6.152H mice (D) at the level of subiculum, DG and 
cortex. 
 
Figure 22. Aβ load and astrogliosis. A-D, Representative images of slices from a 6-month-old wt mouse (A), a 6-month-old 
PS2.30H mouse (B), a 3-month-old B6.152H mouse (C) and a 6-month-old B6.152H mouse (D), where Aβ (left panels) and 
GFAP (right panels) were immunolabelled. Images in the same raw were acquired from the same slice. At 3 months of age, 
B6.152H mice display a strong intracellular accumulation of Aβ and/or Aβ-containing peptides, in particular in the subiculum 
and in the sp layer of CA1. The same layer in CA3 does not mirror the phenomenon. Conversely, in the CA3 subfield the sr 
layer appears diffusely labelled. Insets in C, magnification of a CA3 sp-sr and a subiculum detail, respectively. No deposition 
of amyloid plaques is observable in slices other than from the B6.152H line at 6 months of age (D). Plaques are mainly 
localized in the subiculum and, to a lesser extent, in the DG and in the cortex. Inset in D, magnification of a plaque-containing 
subiculum detail. GFAP labelling markedly increases in 6-month-old B6.152H mice (D) at the level of subiculum, DG and 
cortex. 
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than APP overexpression, this would be in line with previous studies reporting that Aβ 
accumulates with the cells before plaques deposition (Gyure et al. 2001; Wirths et al. 2001). 
Within the framework of the brain inflammatory condition that accompanies AD, astrocytes 
become reactive and increase the expression levels of the intermediate filament protein GFAP, 
this condition being known as astrogliosis (Steardo Jr et al. 2015). We quantified the expression 
of GFAP through the intensity of the staining fluorescent signal as shown in Figure 12. A 
quantitative analysis was carried out within specific regions as defined in Figure 11 and Materials 
and Methods, and summarized in Figure 13. We found a statistically significant increase (p < 
0.05, Mann-Whitney rank-sum test) of mean intensity in the subiculum of 6-old-month B6.152H 
mice, compared to age-matched wt mice (B6.152H, 75.6 ± 6.1; wt, 52.4 ± 5.4), the DG (B6.152H, 
66.0 ± 5.9; wt, 48.2 ± 5.3) and the cortex (B6.152H, 57.0 ± 1.8; wt, 40.0 ± 4.5). 
7.7 AMYLOID ACCUMULATION 
It is now largely accepted that in AD synaptic loss and neuronal dysfunction are caused by 
accumulation of soluble forms of A42, especially small oligomers, rather than by amyloid 
plaques. The accumulation of A42 was thus evaluated at the hippocampal level by means of 
ELISA kits suited to measure both mouse and human A42 (see Materials and Methods). As 
shown in Figure 14, compared to wt mice, the PS2.30H mice have only slightly higher levels of 
A42, which are in the order of few pg/mg of wet tissue. In contrast, the B6.152H mice have 
about 100 times more A42 than wt mice at all the ages, in particular the 3-month-old B6.152H 
mice show  A42 levels about 30 times higher than those found in 6-month-old PS2.30H mice. 
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Figure 25. Hippocampal Aβ42 quantification. The total amount of Aβ42 was obtained by means of ELISA assays. A, Mean 
absolute quantity of Aβ42. Error bars represent ± SEM. *, p < 0.05; **, p < 0.01; ****, p < 0.0001. Student’s t-test. B, Mean 
Aβ42 quantity normalized to the average in 3-month-old wt mice. In both graphs the y-axes is in log-scale. Only in the B6.152H 
line Aβ42 levels are significantly higher compared to wt mice. 
 
  
Figure 26. Hippocampal Aβ42 quantification. The total amount of Aβ42 was obtained by means of ELISA assays. A, Mean 
absolute quantity of Aβ42. Error bars r present ± SEM. *, p < 0.05; **, p < 0.01; ****  p < 0.0001. Student’s t-test. B, Mean 
Aβ42 quantity normalized to the average in 3-month-old wt mice. In both graphs the y-axes is in log-scale. Only in the B6.152H 
line Aβ42 levels are significantly higher compared to wt mice. 
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8 DISCUSSION 
In this work, we explored the electrophysiological alterations in the LFP activity of the DG 
network of two AD mouse models, PS2.30H and B6.152H, which harbor the N141I mutated form 
of PS2, respectively alone or in combination with the Swedish mutation of APP. We acquired the 
LFP signal in the condition of urethane anesthesia and extracted signal features, including 
amplitude, spectral steepness and theta-higher frequencies PAC by means of frequency and 
time-frequency methods. Importantly, to the end of assessing the temporal evolution of the 
features into exam, we investigated three age points, namely 3, 6 and 12 months, i.e before, 
during and after heavy plaque deposition, and we probed the time-matched presence of 
histological hallmarks, in the form of amyloid plaques and astrogliosis, as well as the degree of 
Aβ load. The electrophysiological alterations with respect to wt mice are summarized in Table 1. 
We first address the physiological significance of the observed alterations in the power, PAC and 
steepness categories and, next, we discuss these alterations in the context of the AD literature.  
8.1 HYPER-SYNCHRONICITY: PSD AND PAC 
The LFP, ECoG and EEG signals, when converted in the frequency domain by means of the 
Fourier transform, display a characteristic composition of a broad range of frequencies where, 
importantly, the amplitude exponentially decays as a function of the frequency. In agreement, 
the PSD function of a brain extracellular recording is often defined as 1/fx, where x is the scaling 
exponential of the decay. Concerning the nature of this behavior that is ubiquitously present in 
brain recordings, it has long been debated, whether the 1/fx function decay is a mere background 
noise, differentially propagating as a function of the frequency owing to low-pass filtering 
properties of the tissue (Nunez 1981), or it is a component of brain functioning dynamics 
(Buzsaki 2006b). Only recently, the 1/fx function has been led down to the size of the various 
Table 1. Summary of the significant electrophysiological alterations in comparison with wt mice. 
 3 months  6 months  12 months 
 PS2.30H B6.152H  PS2.30H B6.152H  PS2.30H B6.152H 
SO power - -  - -  - - 
Theta power - -  - -  - - 
Beta power - -  - ↑↑  - - 
SG power - -  ↑ ↑↑  - - 
HG power - -  ↑ -  - - 
Epsilon power - -  - -  - - 
Theta-beta PAC - -  - ↑  - - 
Theta-SG PAC - -  - ↑  - - 
Theta-HG PAC - -  - -  - - 
Theta-Epsilon PAC - -  - -  ↓ ↓ 
PSD slope coefficient - ↑↑↑↑  - ↑↑  - - 
         
↑, increase, p < 0.05; ↑↑, increase, p < 0.01; ↑↑↑↑, increase, p < 0.0001; ↓, decrease, p < 0.05; Mann-Whitney test 
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frequency generators (Logothetis, Kayser, Oeltermann 2007) and has started to be widely 
recognized as a large scale representation of neural activity, thus, as a rich source of valuable 
information on the underlying network operations (Buzsáki, Logothetis, Singer 2013; He et al. 
2010; He 2014). 
The broad band power of extracellular brain recordings was shown to positively correlate with 
neuronal firing rate (Manning et al. 2009) but it is the slope coefficient of the PSD function that 
is funneling the most interest, mainly because it has been demonstrated to change depending 
on the behavioral task. For instance, the x exponential was reduced (i.e., the spectrum flattened) 
during a visual detection task when the subject was presented with an unpredictable stimulus 
(He et al. 2010) as well as in correspondence with sensory and motor responses in a manner that 
was consistent across modalities, yet with specific features (Podvalny et al. 2015). Further, it was 
linked to memory processing, since it diminished in the course of a working memory task with 
the increase of the cognitive load (He 2014). 
Finally, attempts to understand the mechanisms underlying the decrease of the spectral 
steepness point to an enhancement of decoupled firing (Freeman and Zhai 2009; Podvalny et al. 
2015; Voytek and Knight 2015). In this sense, the PSD slope coefficient (or the x exponential of 
1/fx), provides a measure of neuronal firing synchronicity, with increased steepness indicating 
enhanced synchronicity. 
Here, we assessed the steepness of the PSD function represented in the semi-log space as the 
slope coefficient of the PSD linear fitting in the 10 – 100 Hz range. We report an early increase 
of PSD steepness in the B6.152H line at 3 months of age with respect to wt mice. This finding is 
suggestive of a condition of hyper-synchronicity, spontaneously appearing in DG network activity 
under urethane anesthesia. The phenomenon persists at 6 months of age, though a progressive 
reduction of its degree as a function of age is observable. At 12 months of age, B6.152H and wt 
mice no longer differ in terms of spectral steepness. 
Another notable feature of brain extracellular recordings is embodied by nested oscillations, 
where a slower rhythm influences a faster one in a dynamic fashion. CFC, i.e. the relation within 
each pair of nested oscillations, can occur on amplitude-amplitude, phase-phase or phase-
amplitude basis (Canolty and Knight 2010). In the last decade, this latter type of CFC – PAC – has 
drawn much attention, in particular concerning the theta and gamma oscillations. Theta-gamma 
PAC has been consistently described in several regions, including the cortex (Canolty et al. 2006; 
Lee et al. 2005) and the hippocampus (Axmacher et al. 2010; Belluscio et al. 2012; Bragin et al. 
1995). Most notably, theta-gamma PAC increased during a learning task and, further, 
predicticted learning performance (Tort et al. 2009). Finally, reduction of theta-gamma PAC also 
hampered memory performance (Shirvalkar, Rapp, Shapiro 2010). In light of all these 
observations, CFC, in general, and theta-gamma PAC, in particular, are progressively losing their 
connotate of epiphenomenon and becoming recognized as a functional mechanism 
fundamental for brain function. 
We investigated the level CFC existing in our LFP signals between the theta phase and the 
amplitude of beta, SG, HG and epsilon band, respectively, as quantified by means of the GLM. At 
6 months of age, B6.152H mice displayed enhanced PAC compared to wt mice in the theta-beta 
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and -SG classes. These observations indicate a condition of overcoupling in the B6.152H line with 
respect to wt mice, emerging at 6 months of age. Interestingly, while PAC in all classes resulted 
unaffected with respect to wt mice in the PS2.30H line at both 3 and 6 months of age, the two 
transgenic mouse lines reported the strongest difference. Indeed, B6.152H PAC was higher in 
comparison with the PS2.30H line in the theta-beta class both at 3 and 6 months of age and in 
the theta-SG class at the age of 6 months. Moreover, 6-month-old B6.152H mice had also a 
stronger theta-HG PAC than PS2.30H mice. Taken together, these findings possibly suggest a 
slightly lower level of coupling in the PS2.30H line compared to wt mice, that is not possible to 
statistically resolve with the sample size in our hands. Finally, at 12 months of age all classes of 
PAC, resulting altered in the preceding time points of our analysis, appeared realigned to the wt 
mouse levels. All in all, 3- and 6-month-old PS2.30H mice appear unaffected in terms of theta-
higher frequency PAC, contrarily to B6.152H mice that present features of overcoupling at 6 
months of age. An exception is embodied by the theta-epsilon PAC, which was significantly 
reduced in both PS2.30H and B6.152H mice compared to age-matched wt mice at 12 months of 
age. Both transgenic lines, in spite of a strikingly different evolution of their PAC levels within the 
individual classes, appear in line with wt mice at 12 months of age, although the decreased level 
of theta-epsilon PAC that they display might represent the beginning of a different aging pattern.  
While both the PAC and the PSD steepness are referred to as indicators of synchronicity within 
the network, their alterations in the B6.152H line do not fully overlap. However, it is important 
to note that they are not believed to represent the same phenomenon. On the one hand, PAC 
describes the level of modulation that the phase of a carrier frequency exerts on the amplitude 
of faster one and, in other words, it represents the ability of the slower rhythm to affect the 
statistical temporal distribution of neuronal firing. On the other hand, the PSD steepness reflects 
the overall statistics of neuronal firing, with a steeper slope resulting from a shift of neuronal 
firing towards increased synchronicity, thus contributing to the power of the slower oscillations 
(Podvalny et al. 2015). In addition, although we limited our analysis to the modulation brought 
by theta on the higher frequencies oscillations, the LFP signal features a hierarchy of nested 
oscillations in an extensive progression throughout the frequency spectrum (He et al. 2010; 
Lakatos et al. 2005). Hence, the apparent discrepancy between the hyper-synchronicity 
evaluated by means of the PAC and the PSD slope, respectively, could perhaps be overcome if a 
larger combination of phase-frequency/amplitude-frequency pairs were taken into exam. 
Surprisingly, at 3 and 6 months of age, analysis of the PSD steepness resulted in a highly 
significant difference between the B6.152H and the wt line, in spite of a far weaker difference 
resolving these two lines in terms of individual bands power or theta-higher frequency PAC. Yet 
this is somehow predicted by previous studies indicating that, within the same behavioral 
conditions and brain area of interest, the scaling of the PSD is remarkably invariant across 
subjects (Linkenkaer-Hansen et al. 2001; Podvalny et al. 2015). 
In conclusion, PSD steepness, better than theta-higher frequency PAC, is a feature of the 
hippocampal LFP that reliably characterizes the stages of the AD-like pathology in the B6.152H 
mouse model. 
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8.2 HYPERACTIVITY: BETA AND GAMMA POWER 
Quantification of the power within different frequency bands is a rather open and widely used 
approach. However, the physiological significance of power-content changes in a given band 
should be carefully addressed. The power of individual bands is estimated basing on the 
frequency-domain representation of the signal, i.e. the PSD function. As a matter of fact, the 
brain PSD is a combination of oscillatory as well as irregular activities and, as such, it is a complex 
and, unfortunately, poorly understood phenomenon (He 2014). Nevertheless, general 
consensus advocates that while real oscillations determine narrow-band peaks in the PSD, 
broad-band “bulges” represent the spectral counterpart of neuronal firing. This is particularly 
true at frequencies > 30 Hz, as demonstrated by studies reporting that gamma activity (~ 30 – 
100 Hz) correlates with neuronal spiking (Csicsvari et al. 2003) and can even be exploited to infer 
spike trains (Rasch et al. 2008). On the other hand, true forms of oscillatory activities do exist 
even in the higher range of the LFP spectrum (> 100 Hz) (Scheffer-Teixeira et al. 2013). In 
particular, in the hippocampus, ripples (140 – 200 Hz) have long been known (Buzsáki et al. 2003) 
and, recently, high-frequency oscillations (HFO, 120 – 160 Hz) were described (Scheffer-Teixeira 
et al. 2012). 
In the present study, we observed an alteration of the PSD function in the PS2.30H and 
B6.152H models that occurs as a shoulder of increased power in the spectrum encompassing 
the beta range in 3-month-old B6.152H mice and, respectively, the beta-SG and the SG-HG range 
in the B6.152H and PS2.30H lines, at 6 months of age. If the broadband power increase in the 
gamma range may be promptly read as an enhancement of neuronal firing, the same 
phenomenon in the beta range requires more caution. 
Hippocampal beta oscillations are far less studied than SO, theta and gamma activities in this 
region and the interpretation of our observation in relation with them is not straightforward. 
Yet, beta band oscillations have been described in the murine hippocampus. On the one hand, 
they were detected in the range 23 – 30 Hz (“beta2”), in the context of novel object recognition. 
In general, they appear to be linked to the detection of novelty (França et al. 2014). On the other 
hand, burst of beta (~20 Hz) activity, relayed from the pyriform cortex (PC) specifically to the DG, 
were elicited in rats in correspondence with the presentation of odors either from predators or 
organic solvents (Lowry and Kay 2007; Vanderwolf 2001). Both these beta activities just 
described are narrowband and short-lived and do not fit with the broadband shoulder that we 
observe in the B6.152H line at both 3 and 6 months of age. 
From another perspective, positive correlation between broadband power increase and 
neuronal firing activity is not limited to the gamma and higher frequencies bands and was 
described at < 30 Hz LFP frequencies, although to a smaller degree with respect to higher 
frequencies (Manning et al. 2009). In this light, this phenomenon, in spite of the relatively low 
frequency, is likely to reflect an increase of neuronal firing with respect to wt mice, i.e. 
hyperactivity. 
All in all, the power spectrum alterations that we report suggest that both the AD mouse 
models in this study present a condition of neuronal hyperactivity at 6 months of age. 
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In the murine cortex in vivo, it was demonstrated that an optogenetically-operated 
enhancement of fast-spiking (FS) interneuron firing activity at a frequency ranging from 20 to 80 
Hz results in a greater LFP power at the frequency corresponding to the stimulation. Lower 
stimulation frequencies yielded firing of FS interneurons but did not modulate LFP power. 
Conversely, opto-stimulation specifically targeting excitatory pyramidal cells produced an 
increase of LFP power only when provided at 8 - 24 Hz frequency. As for FS interneurons, the 
frequency of LFP power increase matched that of the stimulation (Cardin et al. 2009). 
We speculate that the increase of power in the gamma range might be due to two, possibly 
combined, reasons: (i) an intrinsic hyperactivity and/or hyperexcitability of (FS) interneurons 
within the DG network and (ii) an increase of external drive onto FS interneurons in the DG. For 
instance, neurons in the nucleus basalis of Meynert, which provide a minor source of cholinergic 
input to the hippocampus, were reported to be metabolic hyperactive during MCI (Dubelaar et 
al. 2006). Future experiments aimed at interfering with the synaptic inputs of DG FS interneurons 
(mainly consisting of basket cells) brought by either external afferences or local excitatory 
granule cells will probably shed light on the mechanism/s underlying the increase of gamma 
power in the DG. 
8.3 HYPERACTIVITY/HYPER-SYNCHRONICITY AND AD 
The phenomena of hyperactivity and hyper-synchronicity are both well-known in the clinical 
field of AD. 
Many works have investigated brain activity alterations in patients diagnosed with AD or MCI 
by means of functional imaging techniques, the most popular being the BOLD-fMRI. A stronger 
activation of the hippocampal region was reported in MCI patients while performing a 
recognition memory task. Interestingly, these subjects performed similarly to controls and 
presented no difference in terms of hippocampal volume. On the contrary, the same study 
showed that AD patients displayed fMRI-assessed hippocampal activation similar to controls 
while performing worse at the mnemonic task and exhibiting a reduced hippocampal volume 
(Dickerson et al. 2005) (see Introduction). Subsequent studies, although is the presence of a 
Figure 27. Correlation between 
BOLD-fMRI and LFP signals as a 
function of the frequency. The 
correlation between the 
average BOLD-fMRI signal in the 
auditory cortex during an 
auditory session (BOLD) and the 
fMRI signal predicted from the 
LFP activity in each range (LFP) 
recorded in the same location. 
The correlation is high and 
positive above 40 Hz, indicating 
that the fMRI signal modelled 
basing of the > 40 Hz LFP 
accurately correlates with the 
real signal. Vice versa, in the 5 – 
15 Hz LFP range, the real signal 
strongly negatively correlates 
with the predictors. Adapted 
from (Mukamel et al. 2005). 
 
Figure 28. Correlation between 
BOLD-fMRI and LFP signals as a 
function of the frequency. The 
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certain variability in terms of results (Johnson et al. 2006; Machulda et al. 2003), have overall 
contributed to draw a picture where the beginning of the clinical phase of AD, corresponding to 
MCI, is marked by hyperactivity in the hippocampus as well as other cortical regions (Dickerson 
et al. 2005; Hämäläinen et al. 2007; Pihlajamaki, Jauhiainen, Soininen 2009). Interestingly, along 
with the activation of the hippocampus, a number of genes regulated by the synaptic activity 
were proved to follow the same pattern of early increased and late decreased transcription 
(Bossers et al. 2010; Lau et al. 2013). In particular, increased fMRI-assessed hippocampal 
activation was found in presymptomatic subjects harboring a PS1 FAD mutation. Also in this case, 
FAD mutation carriers performed similarly to control subjects (Quiroz et al. 2010).  
The relation between the fMRI signal and the ongoing electrophysiological activity is not 
completely understood but it is being uncovered (He et al. 2008). The LFP signal recorded from 
the auditory cortex was shown to markedly correlate with fMRI-imaged activation in that same 
area in the course of an auditory task. Importantly, the correlation with the fMRI signal was 
positive for frequencies above 40 Hz and negative for frequencies below 15 Hz in the LFP 
recording. Additionally, correlation declined above 130 - 140 Hz (Mukamel et al. 2005; Nir et al. 
2007). These observations bridge between the neuronal spiking rate in a given region and the 
degree of above-baseline activation of that area, imaged by the fMRI (see Figure 15). 
Hyper-synchronicity, on the other hand, represents a common feature in AD, in the form of 
epilepsy. The incidence of seizures is higher in AD patients than in control groups (Lozsadi and 
Larner 2006) and it reaches even higher levels in the early-onset FAD subjects (Palop and Mucke 
2009) with 32% of PS2-N141I-FAD patients showing seizures (Jayadev et al. 2010). Notably, 
epileptiform activity has been often observed as electroencephalographic seizures associated 
with transient epileptic amnesia (TEA) (Rabinowicz et al. 2000), raising the hypothesis of epileptic 
discharge to be an underestimated phenomenon (Mendes 2002; Palop et al. 2007). Finally, it is 
worth noting that epileptiform activity emerges at very young age in FAD early-onset subjects, 
long before the first cognitive symptoms are detected. 
Taken together, the above described findings provide a framework for the interpretation of 
our results in regard both to the hyperactivity and the hyper-synchronicity. The former, that we 
statistically detect in both our transgenic lines at 6 months of age, is in line with previous studies 
indicating a condition of enhanced fMRI activity in MCI patients, while the latter correlates with 
higher incidence of epilepsy found in FAD families’ pedigrees as well as with the consistent 
observation of TEA in AD patients. 
8.4 HYPERACTIVITY AND AD MOUSE MODELS 
The neuronal hyperactivity that we found in both the transgenic lines investigated, adds to 
similar previous observations obtained from other AD models, in support to the hypothesis 
claiming early neuronal hyperactivity to be a biomarker of AD. 
In particular, neuronal hyperexcitability was demonstrated at 3 – 4 months of age in different 
mice, including the hAPPJ20 line, expressing hAPP with various forms of FAD mutations and it 
was linked with the non-convulsive seizures spontaneously appearing in those mice (Palop et al. 
2007). Subsequently, spontaneous hyperactivity, in terms of increased neuronal firing rate, was 
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reported in hAPPJ20 mice in baseline condition (Verret et al. 2012). Notably, this line is known 
to exhibit plaques deposition starting from 5 – 7 months of age. Further, hyperexcitability, as 
augmented rate of Ca2+ transients, was observed in cortical neurons in the APP23xPS45 line in 
mice 6- to 10-month-old (Busche et al. 2008) and was later reported to occur in the hippocampus 
as well (Busche et al. 2012). Interestingly, while in the cortex the hyperactivity was detectable 
only concomitantly with plaques and, furthermore, in close proximity with these latter (Busche 
et al. 2008), in the hippocampus it was observed also at the age of 1 - 2 months, before plaques 
deposition (Busche et al. 2012). 
In a more direct relation to our study, enhancement of hippocampal gamma power in the 
range ~20 – 45 Hz was reported in freely behaving 4-month-old APP23 mice (Ittner et al. 2014), 
characterized by plaques deposition starting at 6 months of age (Sturchler-Pierrat et al. 1997) 
(but see also (Rubio et al. 2012)). 
As it was already observed (Stargardt, Swaab, Bossers 2015), all the FAD transgenic mouse line 
in which neuronal hyperactivity was described are based on mutated forms of APP and produce 
very high levels of Aβ as well as they exhibit plaque deposition at a very early age. Hence, these 
lines are not suited for addressing the question as whether the hyperactivity per se could be 
responsible, at least partially, of the cascade of events that underlay AD pathology.  Our B6.152H 
line makes no exception. However it is interesting to note that in our study B6.152H mice 
developed a condition of hippocampal hyperactivity at the same age of PS2.30H mice. This 
occurred despite of the drastically different levels of Aβ42 production. In particular, at the time 
point where we found the increased SG-HG power, PS2.30H mice present Aβ levels that are only 
slightly higher than those found in age-matched wt mice, no plaques deposition and no 
significant sign of astrogliosis. In addition, the hyperactivity is no longer detectable in both 
transgenic lines at the late time point of our study. Thus, the hippocampal hyperactivity that we 
report does not seem to correlate with Aβ levels and, considering the mismatch with plaques 
and astrogliosis in the PS2.30H, we speculate not to be a compensatory mechanism (Stargardt, 
Swaab, Bossers 2015). Thus it better correlates to the expression of mutant PS2. Experiments on 
PS2KO mice would possibly shed light on this issue. 
Nevertheless, B6.152H mice exhibit a pattern of alterations of the LFP activity that is more 
complex than in the PS2.30H line. Indeed, in conjunction with the hyperactivity, they also 
present hyper-synchronicity, detectable as early as 3 months of age in form of a steeper PSD 
function decay, or at 6 month age as enhanced theta-beta and theta-SG PAC. Since the hyper-
synchronicity is not detectable in the PS2.30H line at any age, this aspect is possibly attributable 
to the much higher levels of Aβ (and/or astrogliosis) that add on the effects due to mutated PS2. 
Experiments on mice carrying the APP Swedish mutation alone would provide further insight on 
the individual contribution provided by APP and PS2 mutations to the B6.152H phenotype. 
Our results further support the hypothesis of an enhanced neuronal activity to precede the 
first clinical symptoms. 
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8.5 HYPER-SYNCHRONICITY AND AD MOUSE MODELS 
Although no previous report, to the best of our knowledge, addressed neuronal synchronicity 
as measured by the PSD steepness in AD mouse models, nonetheless many studies have pointed 
to an increased spiking synchronicity as a common feature of mouse lines expressing mutated 
forms of APP. Epileptiform activity has been consistently found in several mouse lines expressing 
mutated APP, including hAPPJ20 (Palop et al. 2007), APP23 (Ittner et al. 2014), Tg2576 
(Westmark et al. 2008) and CRND8 (Del Vecchio et al. 2004). In particular, not only sporadic 
seizures were described to spontaneously appear in freely behaving animals (Ittner et al. 2014; 
Palop et al. 2007; Westmark et al. 2008) but, in addition, the hyper-synchronicity emerged as an 
enhanced tendency to the development of seizures after administration of riluzole (Ittner et al. 
2014; Verret et al. 2012), a voltage gated sodium channel blocker, or pentylenetetrazol (Del 
Vecchio et al. 2004; Westmark et al. 2008), a GABA-A receptor antagonist. 
As for the hyperactivity (see previous paragraph), all the mentioned AD models are based on 
the overexpression of APP and it is, thus, difficult to estimate the individual contribution of Aβ 
and APP overexpression to the observed hyper-synchronicity. Born and collaborators specifically 
addressed this issue by generating a controllable APP-transgenic model in which APP expression 
was under the control of the Tet-Off system and could be reduced by about 80% through the 
administration of doxycycline (DOX). They found that their Tet-Off APP line presented increased 
synchronicity and seizures and that APP knock-down by administration of DOX, decreased APP 
and Aβ levels and reversed the altered phenotype. Conversely, selective decrease of Aβ through 
the administration of a γ-secretase inhibitor, LY411575, did not rescue the phenotype in spite of 
the significant reduction of Aβ levels. Finally, the authors tested for the presence of seizures and 
hyper-synchronicity the EEG of the AD model APP/PS1, where APP levels are similar to the wt 
ones, yet Aβ levels are boosted and amyloid plaques are formed. In this latter case they found 
neither spontaneous occurrence of seizure nor spectral alterations. They concluded that the 
aberrant synchronicity and the susceptibility to seizures in the Tet-Off APP line, as well as in the 
other APP-overexpressing lines previously described, is possibly due to APP overexpression per 
se or to an APP fragment other than Aβ (Born et al. 2014). 
In agreement with the previous studies just summarized, we found a marker of increased 
synchronicity only in our B6.152H line, which overexpresses APP. 
Interestingly, in the B6.152H line we observed a significant astrogliosis at 6 months of age 
contextually with the appearance of the extracellular amyloid deposits. Very recently, a clinical 
study described astrogliosis to emerge and then decline in the preclinical phase of FAD. The 
extension of our GFAP-expression analysis to 12-month-old mice would allow to evaluate the 
degree to which this aspect of FAD is reproduced in the B6.152H line (Rodriguez-Vieitez et al. 
2016). 
8.6 CALCIUM DYSHOMEOSTASIS 
We report a significant increase of neuronal activity in the DG of PS2.30H mice in spite of the 
lack of amyloid plaque deposition and astrogliosis and similar levels of total Aβ42, with respect 
to age-matched wt mice. These results stand in favor of the mutant PS2 to play a role in network 
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activity alteration through, possibly, the documented dysregulation of Ca2+ homeostasis or other 
yet unknown effects, either dependent or independent on -secretase activity. 
PS1 and PS2 mutations have been shown to directly affect the ER Ca2+ signaling, mainly by 
altering the IP3R- and RyR-mediated Ca2+ release (Del Prete, Checler, Chami 2014). Moreover, 
PS2 enhances ER Ca2+ leakage (Brunello et al. 2009) and mitochondrial Ca2+ uptake. This latter 
aspect relies on the closer ER-mitochondria interaction realized by the mutant PS2 (Kipanyula et 
al. 2012; Zampese et al. 2011a). In vivo, enhanced Ca2+ activity has been reported only in mouse 
models expressing hAPP along with a mutant form of hPS1 (Busche et al. 2012; Kuchibhotla et 
al. 2008). Here, we show that the expression of the mutant N141I form of PS2 alone is sufficient 
for the development of a phenotype of neuronal hyperactivity. Although the relation between 
the hyperactivity that we observed and Ca2+ dyshomeostasis remains to be investigated, it is 
tempting to speculate a connection among our finding, the early ER/mitochondria Ca2+ 
dysregulation observed in vitro (Kipanyula et al. 2012) and the enhanced neuronal Ca2+ activity 
reported in vivo (Busche et al. 2008; Busche et al. 2012). 
Notwithstanding, it should be noted that, in our PS2.30H mice, the mutant PS2 is expressed 
not only in neurons but also in astrocytes (unpublished data) and in the two mouse lines, both 
neurons and astrocytes display altered Ca2+ homeostasis (Kipanyula et al. 2012). Hence, a 
possible role of astrocytes in the hyperactivity described here is to be taken into account. 
8.7 RESPIRATION AND HIPPOCAMPAL THETA 
As a last observation, we discuss here a peculiar aspect of the theta oscillations that we 
investigated. 
Two types of hippocampal theta oscillations have classically been defined as type I (atropine-
insensitive) or type II (atropine-sensitive) on the basing of their sensitivity to muscarinic 
acetylcholine receptor antagonists (Buzsáki 2002). The cholinergic theta rhythm is known to rely 
on muscarinic receptors involving phospholipase C (PLC) and, at least partially, the voltage-gated 
Ca2+ channel 2.3 (Cav2.3) (Müller et al. 2012; Shin et al. 2005). Moreover it is elicited in the 
hippocampus by MS-DBB cholinergic input and, importantly, used to be the only one 
acknowledged under urethane anesthesia (Kramis, Vanderwolf, Bland 1975). However, a new 
theta rhythm has been recently described in the hippocampus of urethane-anesthetized 
animals, after noxious stimulation (Yanovsky et al. 2014). This rhythm, called HRR, differs from 
the classical type II theta in that it is atropine-resistant. Most notably, HRR is entrained by nasal 
respiration and it is strongest in the hilus of the DG. 
By recording the LFP signal from the DG of urethane-anesthetized mice, we observed a 
prominent oscillatory activity, generally peaking between 2 and 3 Hz. This rhythm had the same 
frequency of the respiratory activity and followed its same fluctuations. This observation is 
consistent with the atropine-resistant HRR described in the murine hippocampus under 
anesthesia after noxious stimulation (Yanovsky et al. 2014). However, being the oscillations in 
our study spontaneously generated, theta rhythm would be expected to be of the type II 
(atropine sensitive) (Kramis, Vanderwolf, Bland 1975).  
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In addition, under urethane anesthesia windows of theta oscillations have been described to 
alternate with moments dominated by SO (Kiss et al. 2013; Pagliardini, Gosgnach, Dickson 2013; 
Shin et al. 2005) and, on this ground, urethane has been proposed to induce a sleep-like 
condition (Clement et al. 2008; Pagliardini, Gosgnach, Dickson 2013). Conversely, not only we 
could not identify a clear alternation of theta versus SO phases but also the SO power often 
coherently followed the fluctuations of the theta rhythm. 
Taken together, the fact that we acquired the LFP signal from the DG, where the HRR is most 
prominent, along with the observations that, in our data, the theta rhythm (i) had the same 
frequency of respiration, (ii) did not alternate with SO and (iii) was particularly low in terms of 
frequency, suggest that it could be a form of spontaneous HRR. Nevertheless, for HRR has so far 
been described only after noxious stimulation, it is not clear at this stage whether the 
spontaneous theta activity that we observed could be atropine sensitive or resistant. 
Pharmacological experiments with administration of muscarinic antagonists (e.g., atropine or 
scopolamine) will be needed to elucidate this specific aspect. 
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9 CONCLUSIONS AND PERSPECTIVES 
In the hippocampus of the AD mouse models PS2.30H and B6152H, we report two different 
patterns of electrophysiological alterations occurring at the level of the spontaneous network 
activity in the hippocampus respectively of PS2.30H and B6152H mice (see Table 1). 
In the PS2.30H line, which expresses the N141I mutant form of PS2, we found neuronal 
hyperactivity at 6 months of age, detected as an increased spectral power in the SG-HG range. 
This phenomenon occurs in the absence of amyloid plaque deposition and astrogliosis in mice 
which also exhibit levels of Aβ42 only slightly higher than wt mice. Hence, this alteration appears 
to be caused by the mutant human PSEN2 transgene through an Aβ-independent mechanism. 
From this perspective, the PS2.30H line results to be an appropriate model for studying the 
effects of the mutant PS2, i.e. Ca2+ dyshomeostasis and neuronal hyperactivity, separated from 
amyloidosis/gliosis. Further, it has been proved that other PS mutations behave as loss-of-
function (Shen and Kelleher 2007). Hence, it will be of interest to investigate the presence of 
network hyperactivity in the PS2KO line, that is now also available to our group. 
The B6.152H mice, which express the mutant PS2 in combination with the Swedish APP 
mutation, present neuronal hyperactivity in the beta-SG range at 6 months of age, overlapping 
with the PS2.30H line, although the frequency range was left-shifted. In addition, B6.152H mice 
were characterized by hyper-synchronicity in the form of both a theta-beta and -SG overcoupling 
and a steeper power spectrum. This latter, was observed as early as 3 months of age – the 
earliest time point of our study – preceding plaques deposition and astrogliosis. However, it 
emerged in a context of strong APP overexpression and Aβ42 production. Likewise, neuronal 
hyper-synchronicity has been described in many models expressing FAD mutant forms of hAPP 
(Born et al. 2014; Verret et al. 2012). Therefore, we speculate that the hyper-synchronicity that 
we observed in our B6.152H mice, unlike the hyperactivity, is more directly due to the APP/ Aβ42 
overexpression. In future experiments, the inclusion of the single transgenic mouse line 
expressing only the Swedish hAPP will help elucidating this point. Finally, a study aimed at 
reducing the Aβ level reduction, for instance by acute γ-secretase inhibition according to (Lanz 
et al. 2003), will provide hints on the specific contribution of APP and Aβ (Born et al. 2014; 
Busche et al. 2012). 
In the B6.152H line the hyper-synchronicity was an early marker as it preceded plaque 
formation and astrogliosis as well as it anticipated the known cognitive decline (Ozmen et al. 
2009), which is first detected at 8 months of age. Yet, the most interesting aspect related to this 
finding is the robustness of the statistical resolution between B6.152H and wt mice basing on 
the spectral slope. The idea of assessing the PSD-function features as a way to address network-
level alterations in the context of neurological disorder is vary recent (Podvalny et al. 2015; 
Voytek and Knight 2015; Voytek et al. 2015). By exploiting this concept in computing the PSD 
slope coefficient, we found that, in spite of the relatively small number of animals and the large 
variability exhibited by the other investigated parameter, the PSD steepness provides a very high 
statistical significance of the difference between the groups (p < 0.0001), indicating that it is 
highly invariant across subjects within the same group. The PSD slope coefficient is a very 
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straightforward parameter to compute from an LFP or EEG recording and might represent a 
valuable biomarker. The extension of this approach to other AD mouse models exhibiting hyper-
synchronicity and/or seizures will permit to validate our conclusion. Moreover, further 
investigation of cortical recordings will allow to evaluate its ultimate utility in the EEG settings. 
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